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Abstract 
Vitamin B12 or cobalamin, a water soluble coenzyme, plays major roles in several 
biochemical pathways resulting in the production of other intermediate substance 
important in DNA replication as well as several neurological activities. Deficiency of 
vitamin B12 can lead to a wide spectrum of hematological and neuropsychiatric 
disorders that can often be reversed by early diagnosis and prompt treatment. 
 
Our study aimed to compare the results of the four widely used automated analyzers for 
vitamin B12 assay in the West Bank / Palestine.  The machines compared were; Abbott 
AxSYM®, ADVIA Centaur®, Immulite®2000, and TOSOH®. Thirty adult 
participants have been chosen. Serum samples have been run in three different clinical 
laboratories in Ramallah city on four different automated analyzers. 
   
A Pearson’s correlation coefficient (r) was computed to assess the correlation between 
the four machines. There was a positive significant correlation between each pair of the 
machines. With varying degrees of correlation between the comparative pairs; r ranged 
from 0.67 to 0.90. However, significant correlation does not mean agreement between 
machines or methods. The result of the slope also varies, with slopes ranging from 0.69 
to 0.81. The y-intercept which reflects the constant bias (difference) between the 
methods also varies widely, with values ranging from 32.2 to 134.6. Despite the 
presence of a significant positive correlation between all comparative pairs, none of 
them met the conditions for methods agreement. Conditions for methods agreement 
are: r > 0.95, y- intercept close to zero and slope of the best –fit- line must be between 
0.9 and 1.1.  
 
The precision of the compared analyzers (reflected by the coefficient of variation (CV)) 
matches with that claimed by the manufactures. Relatively good precision has been 
obtained from the four methods. However, only one sample agreed upon; this sample 
was low in vitamin B12 concentration when measured by each of the four machines. 
Otherwise, variability of results was inconsistent and very high among the four 
machines. Some machines gave double the result of the others. This inconsistency in 
results can be attributed to a sample factor that requires further investigations.   
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This study confirms the presence of variations in the serum vitamin B12 results 
between different analyzers/ methods. Physician and lab-technicians should start 
including the metabolic products tests (tHcy and MMA) in their routine work when 
serum vitamin B12 result is in the gray area.  
 
In conclusion, an isolated abnormal result of serum vitamin B12 should not be the sole 
criterion on which treatment decisions are made. A repeat assay, other confirmatory 
tests, and the clinical evaluation of the patient are necessary prior to a diagnostic 
conclusion.  
 
 v
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Chapter One: 
 
1.1. Introduction. 
 
Vitamin B12 or cobalamin, a water soluble coenzyme, plays major roles in several 
biochemical pathways that resulting in the production of other intermediate substances 
important in DNA replication as well as several neurological activities (Rodgers and 
Young, 2005). It is one of the complexes containing cobalt as central atom attached to 
different groups or ligands (Vogeser and Lorenzl, 2007).  
 
Deficiency of vitamin B12 can lead to a wide spectrum of hematological and 
neuropsychiatric disorders. Studies mention that 15% of the individuals above 65 years old 
have laboratory evidence of vitamin B12 deficiency (Oh and Brown, 2003). Vitamin B12 
deficiency is associated with macrocytic (megaloblastic) anemia and pancytopenia. 
Neurologic sequencing from vitamin B12 deficiency includes paresthesias, peripheral 
neuropathy, irritability, personality change, mild memory impairment and depression (Oh 
and Brown, 2003). When listing the consequences of vitamin B12 deficiency, we cannot 
ignore the effect of increased hemocystein level as a result of both folate and vitamin B12 
deficiency in increasing the risk for thrombosis (Lewis et al., 2006). 
 
Although the body stores of vitamin B12 are sufficient for at least two years the deficiency 
features still appear. The hematological abnormalities can be reversed by either vitamin 
B12 supplements or folate supplement. Folate can overcome or mask B12 deficiency since 
vitamin B12 itself is not involved in DNA synthesis by itself; while it is so important in 
recycling of folate. Folate in turn is an essential cofactor in thymidylate synthesis which is 
a rate limiting step in DNA synthesis, that’s how you can by increasing the folate intakes 
overcome megaloblastic anemia (Rodgers and Young, 2005). Another important role of 
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B12 is its role in S-adenosyl-methionine synthesis pathway, the only way to donate methyl 
group essential in several reactions in brain proteins, membrane phospholipids and 
neurotransmitters production (Rodgers and Young, 2005).        
     
Causes of vitamin B12 deficiency can be divided into three classes: nutritional deficiency, 
malabsorption syndromes and other gastrointestinal causes. Nutritional deficiency is 
common especially in old age people and in vegetarians. A malabsorption syndrome is 
another cause of deficiency. It is characterized in pernicious anemia, an autoimmune 
disease that affects the gastric parietal cells and so impaired the production of intrinsic 
factor and subsequently limits vitamin B12 absorption. Other causes of vitamin B12 
deficiency include; chronic gastrointestinal symptoms, Zollinger-Ellison syndrome, 
Crohn’s disease, patients with a history of intestinal surgery, the bacterial overgrowth that 
can compete for dietary vitamin B12 in the small bowel, the infestation with tapeworms or 
other intestinal parasites, and congenital transport-protein deficiencies, including 
transcobalamin II deficiency (Oh and Brown, 2003). Genetic factors may also play a role 
in B12 deficiency and the case of methylene tetrahydrofolate reductase polymorphisms is 
an example (Lewis et al., 2006). 
     
As mentioned above, a chronic gastrointestinal disease is a major cause for B12 deficiency. 
This fact could be explained by understanding the vitamin B12 absorption cycle, where the 
acidic environment of the stomach facilitates the breakdown of vitamin B12 that is bound 
to food. The intrinsic factor, released by parietal cells in the stomach and binds to vitamin 
B12 in the duodenum. This complex subsequently aids in the absorption of vitamin B12 in 
the terminal ileum. Once absorbed, vitamin B12 binds to transcobalamin II and is 
transported throughout the body (Oh and Brown, 2003). Nearly 99% of serum B12 is 
bound to transcobalamin so the releasing step in the assay steps is so important (Lewis et 
al., 2006). 
      
Different methods for vitamin B12 determination are now present; some of the methods 
have been mentioned in our previous work (Karmi et al., 2011). The microbiological 
method was considered as the “reference” and a traditional method. Actually, there is no 
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internationally reference method for B12 determination but the British standers chose the 
microbiological method as a reference one. It is minimally used now-a-day in the clinical 
laboratories but may be used to evaluate the automated methods (Lewis et al., 2006). The 
microbiological method first described by Ross (1950) using Euglena gracilis as test 
organism (Karmi et al., 2011). Other methods include the radioassay method, 
immunoassay, nonisotopic competietive protein binding assay, and mass spectrometry 
(Lewis et al., 2006). Because those methods are not all available for the routine clinical use 
for total serum cobalamin assay, the use of ligand binding methods at present as a 
screening test in suspected cobalamin deficiency cases are getting wider (Vogeser and 
Lorenzl, 2007) despite  the limitations of this assay. The specificity of the total vitamin 
B12 assay is about 50%; this means that only 50% of the patients will have low level of 
B12 and clinical evidence of deficiency. While the sensitivity of it is about 95%, that is, 
5% of the patients are clinically deficient with normal level of serum vitamin B12 (Lewis 
et al., 2006). So, one cannot rely solely on the serum vitamin B12 result to diagnose 
vitamin B12 deficiency; because of these limitations mentioned, the importance of other 
tests appears. Such diagnostic and confirmatory tests are; Methylmalonic acids (MMA), 
plasma hemocystin, and other vitamin B12 derivatives. (Vogeser and Lorenzl, 2007; Lewis 
et al., 2006).  
        
Our study aims to compare the results of the four widely used automated analyzers for 
vitamin B12 assay in the West Bank of Palestine.  The machines to be compared are; 
Abbott AxSYM®, ADVIA Centaur®, Immulite®2000, and TOSOH®. This will be the 
first study to be done in Palestine for this purpose. 
 
1.2. Vitamin B12; the history, structure, and bioavailability. 
  
Physicians were always fascinated about the causes of diseases. In 1897 the term 
“deficiency diseases “appeared to include all the diseases that are not caused by germs or 
toxics. Since - in that time - physicians were not able to isolate all of the diseases causative 
agents, they call some of the diseases causative agents as “unknown substances or factors”. 
Vitamins were some of this “unknown causes”; their deficiency was a cause for different 
diseases that time. Later and in 1905, Cornelius Adrianus Pekelharing found that animals 
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fed with purified proteins, carbohydrates, fats, inorganic salts, and water would thrive only 
if small amounts of milk were added to the diet. So they thought that milk contains 
“unrecognized agents” that is essential for growth and needed in small quantities. One of 
the” deficiency diseases” that attracts the physicians interests that time is the disease 
known as polyneuritis in animals and beriberi in humans. The secret cause of this disease 
have been resolved after a Dutch physician Christiaan Eijkman noticed that the disease 
appeared only in chickens restricted to polished rice diet, and so, changing the animals diet 
to unpolished rice or rice polishing will cure it. In 1911, Casimir Funk isolated a 
concentrate from rice polishing that cured polyneuritis in pigeons, he named the 
concentrate “vitamine” because it appeared to be vital to life and because it was probably 
an amine. That was the story of the word “vitamin”. From that time the name stuck to what 
was previously called “accessory food substances”. It was not before 1920 when Jack Cecil 
Drummond suggested that, since there was no evidence to support the original idea that 
these constituents were amines, the final “e” have been dropped (Rosenfeld, 1997). 
 
This year 2014, marks the 80th anniversary of the Noble Prize shared by Whipple, Minot, 
and Murphy for their discovery that raw liver contained a substance, the “anti-pernicious 
anemia” factor, which reversed this anemia in dogs and humans. It also marks the 50th 
anniversary of Dorothy Crowfoot Hodgkin’s Noble prize for her X-ray diffraction work on 
numerous important biomolecules, including, of course, the landmark crystal structure of 
vitamin B12, and is also the 18th anniversary of her death (Froese and Gravel, 2010). 
Martens (2002) actually presents a good historical overview of vitamin B12 including  its  
discovery, the isolation, the crystallization, and even the resolution of the crystal structures 
of B12 dependent enzymes and the different forms discovered. (Martens et al., 2002). 
 
Vitamin B12 belongs to corrinoids family which represents the tetrapyrrole components 
(Kumar et al., 2010). As mentioned above, the structure of vitamin B12 was first solved by 
Hodgkin in 1964, using x-ray crystallography (Froese and Gravel, 2010).  The structure of 
vitamin B12 is very complicated, actually the most chemically complex vitamin known 
(Froese and Gravel, 2010; Kumar et al., 2010). It is large organometallic molecule, range 
approximately form 1300–1500 Dalton in size (Kumar et al., 2010; Martens et al., 2002).  
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Vitamin B12 was very attractive material to study by chemists may be due to its unique 
ligands bound to it. Four of the ligands are the nitrogen atoms of the planar corrin ring that 
surround the cobalt atom. The α-axial ligand, extending below the corrin ring, is nitrogen 
of the 5,6 dimethylbenzimdazole (DMB), phosphoribosyl moiety that also attaches back to 
the corrin ring through one of its propionamide side chains. The upper or β-axial ligand 
varies, depending on the modification state of cobalamin (R-group), (Froese and Gravel, 
2010; Kumar et al., 2010). This R group could be either an adenosyl group, cyano group, 
or a methyl group. Corrinoids also include vitamin B12 analogs as members in this wide 
family. The natural forms of vitamin B12 are hydroxylcobalamin (OH-Cbl), 
methylcobalamin (Me-Cbl) and 5-deoxyadenosylcobalamin (Ado-Cbl) which considered 
as the biological active form. Those forms are the final products for B12-biosynthesis in 
bacteria, while cyanocobalamin (CNCbl), is the industrial form and the most stable one 
which are similar in structure to cobalamin, but they are inactive or functionless in human 
systems, and are not bound by the protein intrinsic factor (IF).Whereas, natural forms of 
vitamin B12 have a strong affinity toward IF for complete absorption to those forms. As 
examples on vitamin B12 analogs: Cobyrinic acid hexaamide, Cobinamide (factor B), 
Cobamide, and Pseudo-vitamin B12 (Kumar et al., 2010).  
 
Those derivatives or what as they called “analogs” are the results of changing of the R 
group in some anaerobic bacteria, or even when the R group is not presents at all as in 
pseudo-vitamin B12 (Martens et  al., 2002). The Me-Cbl, Adl-Cbl, and OH-Cbl 
compounds are known to be sensitive to light, and once they are isolates they have to be 
transformed into the more stable form CN-Cbl by the addition of cyanide (Kumar et al., 
2010). 
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Figure 1.1: Vitamin B12 structure. Adapted from: (Kumar et al., 2010).   
 
This unique structure gives vitamin B12 unique biochemical proprieties as well, and so this 
unique structure also contributes to the reactivity and function of this molecular. The 
reactivity is not the function of the different R groups attached to the corrin ring only, but 
there is another two important factors contribute to that; whether the DMB is coordinated 
to cobalt in the lower axial position, and the oxidation state of the central cobalt atom. The 
cobalt atom of cobalamin may exist in three different oxidation states which are; the +3 
[cob (III) alamin], +2 [cob (II) alamin] or +1 [cob (I) alamin] oxidation state. AdoCbl, 
MeCbl, CNCbl and OHCbl, all of which are cob (III) alamins with the DMB nitrogen base 
coordinated to the cobalt in the lower axial position (Froese and Gravel, 2010).When bind 
to MeCbl and AdoCbl, methylmalonyl- CoA mutase and methionine synthase enzymes  
replaced the DMB nitrogen by a histidine of the enzyme (Froese and Gravel, 2010). 
 
Despite their great dependence on vitamin B12, animals including humans, do not 
synthesize it, otherwise they depends on some bacteria and archaea which solely 
synthesize it, whereas, plants and fungi are thought to neither synthesize nor use it. Reports 
mention that if vitamin B12 presents in plants, fungi or yeast it may be due to bacterial 
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contamination (Martens et al., 2002). It has been suggested that vitamin B12 is an 
extremely old molecule in evolution (Froese and Gravel, 2010). 
1.3. Vitamin B12; the dependent reactions in bacteria.  
 
Unlike mammals and other higher eukaryotes which have only two cobalamin-dependent 
enzymes, methylmalonyl- CoA mutase and methionine synthase, prokaryotes depends on 
cobalamin as cofactor for different enzymes. These enzymes include three classes of 
AdoCbl-dependent mutases, the isomerases (e.g. MCM, ribonucleotide reductase, 
glutamate mutase), the eliminases (e.g. diol dehydratase) and the aminomutases (e.g. 
Dlysine- 5, 6-aminomutase), as well as the MeCbl-dependent methyltransferases (e.g. MS) 
and the vitamin B12-dependent reductive dehalogenases (e.g: 3–6chloro-4-
hydroxybenzoate dehalogenase). (Martens et al., 2002). Other detailed information about 
the vitamin B12 biosynthesis and function in bacteria could be found in J. H. Marten’s 
mini review (Martens et al., 2002). 
 
Almost about 10 years was the time interval has been taken by Woodward and 
Eschenmoser to illustrate vitamin B12 chemical production. With the participation of more 
than 100 researcher, their work has been crowned in 1973 by the illustration of the 
biochemical pathway for cobalamin synthesis. Nevertheless their illustrated way is not the 
way followed now a day in vitamin B12 commercial production, since it is very 
complicated, involving more than 70 synthesis step, which make it also an expensive 
process. In contrast to the chemical way of synthesis, the biosynthesis of vitamin B12 
using genetically optimal microorganisms considers the commercially accepted and the 
preferred way to produce vitamin B12 supplements now days (Martens et al., 2002). 
 
Among the B12-producing species are the following genera: Aerobacter, Agrobacterium, 
Alcaligenes, Azotobacter, Bacillus, Clostridium, Corynebacterium, Flavobacterium, 
Micromonospora, Mycobacterium, Norcardia, Propionibacterium, Protaminobacter, 
Proteus, Pseudomonas, Rhizobium, Salmonella, Serratia, Streptomyces, Streptococcus and 
Xanthomonas (Martens et al., 2002). Those are some of the common microorganism 
species that have been used in vitamin B12 production. Logically, naturally high vitamin 
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B12 producers and rapid growth species are the optimal for the industrial production, since 
the two characteristics shared by the two strains Propionibacterium shermanii and 
Pseudomonas denitrificans, one may think that genus Propionibacterium have been 
preferred in this industry, because this genus have obtained the GRAS (generally 
recognized as safe) status from the United States Food and Drug Administration, but the 
non expected truth is that P. denitrificans is the most one has been used by the main B12-
producing company, which cover more than 80% of the world production of vitamin B12, 
“Aventis”(a company appears from the fusion of two companies; Rhône-Poulenc Rorer 
”RPR” (France) with Hoechst AG (Germany)), this genetically engineered P. denitrificans 
used by Rhône-Poulenc Rorer supposed to reach a productivity of 100–300 mg/L. The 
optimal culture conditions for the production of vitamin B12 using Pseudomonas 
denitrificans could be summarized in the needs for the aeration during the whole 
fermentation process of about 2–3 days at 30 °C and pH values are maintained at 6–7 with 
the presence of sucrose as a main component in the culture medium (Martens et al., 2002). 
. 
 In contrast to Pseudomonas denitrificans, Propionibacterium strains dependent method is 
divided into two stages; in the first 3 days of fermentation, the bacteria are grown 
anaerobically to produce the vitamin B12 precursor cobamide, (a vitamin B12 intermediate 
missing the DMBI moiety), then, vitamin B12 formation is completed by gentle aeration of 
the whole culture for 1–3 days, allowing the bacteria to undertake the oxygen-dependent 
synthesis of the DMBI. The final steps in vitamin B12 production are the extraction and 
purification steps: the harvested cells suspension is heated at 80–120 °C for 10–30 min at 
pH 6.5–8.5 in order to extract the vitamin B12. While the next step is the conversion to 
cyanocobalamin (the most stable form) this is done by treating the heated broth or cell 
suspension with cyanide or thiocyanate. Then filtration or precipitated with auxiliaries 
tannic acid or cresol produce 80% pure vitamin B12, which is suitable for animal feed. 
Further purification and crystallization need for the production of cyanocobalamine to be 
used as food supplements (Martens et al., 2002). 
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1.4. Vitamin B12 absorption and malabsorption: 
 
One of the well known facts about vitamin B12 is the non ability of mammalian synthesis 
for this vital organo-molecule. The question that may arise from this fact is: if the 
microorganisms in the mammalian large intestine are able for vitamin B12 synthesis, then 
why this great dependence on the acquired dietary intake of it? The answer for this logic 
question is actually simple when remembering that the absorption of vitamin B12 could 
not take place in the large intestine, while only the upper small intestine is the absorption 
site. So that, human depends on the natural sources such as; liver, kidney, meat, fish, dairy 
products, eggs, and shellfish. The average daily intake is about 4 μg, whereas the 
physiological needs are only 0.5-1.0 μg (Schjonsby, 1989; Froese and Gravel, 2010).       
 
The absorption of vitamin B12 starts in stomach where it has to be released from dietary 
proteins, and then binds to R-protein or haptocorrin (Schjonsby, 1989; Froese and Gravel, 
2010).The acidity of the stomach accompanied to pepsin actually facilitates the releasing 
process for dietary protein, but it is not the only factor play a role; food sources, and 
cooking and food preparation may also play a role. It has been proved that gastric juice R-
proteins are found in many body fluids rather than gastric fluid, including; saliva, bile, 
intestinal juice, and serum (Schjonsby, 1989). 
 
Vitamin B12 remains bound to R-protein until pancreatic proteases in upper small intestine 
partially degrade R-protein and enable vitamin B12 to bind to intrinsic factors ”IF”. The 
journey of vitamin B12 absorption continues in the ileum, where the vitamin B12-intrinsic 
factor complex attaches to specific membrane receptors which are located at the bottom of 
the pits between the microvilli, in the entire distal of the human small intestine (Schjonsby, 
1989; Froese and Gravel, 2010). The attachment is highly specific, means that the receptor 
does not take up vitamin B12 bound to binders other than intrinsic factor nor does it take 
up vitamin B12 analogues. Have to know also that the binding site on vitamin B12 for 
intrinsic factor is separate from that which attaches to the receptor, means that the 
abnormal intrinsic factors bind vitamin B12 normally and also react normally with 
antibody to intrinsic factor, but it cannot attach to the receptor (Schjonsby, 1989). This 
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highly specific attachment considered as the first screening mechanism to prevent 
degraded cobalamins from being intracellular taken (Froese and Gravel, 2010). The 
receptor is composed of a heterodimer of amnionless and cubilin, called cubam (Froese 
and Gravel, 2010) and megalin, an associated membrane transport protein (Koury and 
Ponka, 2004). 
 
Although the receptor has not been fully characterized, the attachment optimal conditions 
have been well studied and summarized in the need for the presence of calcium-ions and a 
neutral pH (Schjonsby, 1989). The next event in the vitamin B12 absorption series occurs 
in inside the cell, where IFs are degraded in the lysosomes and vitamin B12 is released into 
the cytosol, from where it has to be transported and released into the bloodstream (Froese 
and Gravel, 2010). The fate of intrinsic factor is unclear; since it is not absorbed into the 
blood, so, it has to be transported into the cell along with vitamin B12, or it may be 
released at the cell surface (Schjonsby, 1989). 
 
 Our vital element “vitamin B12” is now in the bloodstream where it has to be bind to 
either haptocorrin (HC) or transcobalamin II (TC). Around 75–90% of plasma cobalamin 
binds HC, this amount binds HC is not involved in cellular cobalamin uptake, thats why 
individuals who have deficient or absent HC have serum cobalamin values in the deficient 
range, but show no sign of cobalamin deficiency. Only 10–25% of plasma cobalamin binds 
to transcobalamin (that is produced by the microvascular endothelium of ileal villi (Koury 
and Ponka, 2004)), and this is the part of cobalamin actually uptakes by the cells (Froese 
and Gravel, 2010). 
 
Congenital abnormalities such that mutations occurs in the gene encoding TC (TCN1) 
result in severe tissue cobalamin insufficiency, megaloblastic anemia, failure to thrive or 
even neurological complications, despite normal plasma cobalamin level. This feature of 
cobalamin deficiency could be reversed by raising the plasma level to very high levels of 
cobalamin so that some tissue may take up unbound cobalamin (Froese and Gravel, 2010). 
This treatment strategy resembles some how the oral administration of high dose of 
cyanocobalamin, which according to Alfred Doscherholmen and Paul S.Hagen 
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experiments may increase the plasma level of cobalamin in pernicious anemia patient 
(Doscherholmen and Hagen, 1957 ). It is also important to mention that TC, like IF, is 
very specific for cobalamin rather than its analogous (Froese and Gravel, 2010). 
 
Of course, vitamin B12 absorption journey could not be finished elsewhere, it is finished 
here in liver, the place where vitamin B12 has to be conserved and stored, and where the 
cobalamin analogous released through bile to outside the body (Schjonsby, 1989).    
 
The malabsorption of vitamin B12 has different causes, and so, different 
pathophysiological basics. Any abnormality in the gastric function or total gastrectomy 
cause deficiency of intrinsic factor, and so, malabsorption of vitamin B12. While the 
partial gastrectomy decreases the plasma level of vitamin B12 without significant 
hematological or neurological abnormalities. The deficiency or the insufficient production 
of intrinsic factors called “pernicious anemia”. Pernicious anemia could also be congenital 
occurs before the age of two, where there is no production to IFs at all, but the gastric 
structure and function is normal (Schjonsby, 1989).  
 
Another cause for vitamin B12 malabsorption is the pancreatic insufficiency. The secretion 
of pancreas -which includes sodium bicarbonate - is required for optimizing the pH for the 
absorption process of the vitamin B12-intrinsic factor complex. Not only for pH but also it 
is believed that the pancreatic secretion contains enzymes that play role in appropriate 
absorption (Schjonsby, 1989). 
 
Actually, vitamin B12 in some cases may be absorbed normally, till it reaches the 
intestinal lumen, where the bacterial over growth may take up and consume the intrinsic 
factor bound vitamin B12, and that cause is another suspected one that may results in 
vitamin B12 malabsorption. This condition is treated by antibiotics to reduce the over 
growth of normal flora (Schjonsby, 1989). Ileal diseases such as coeliac disease, tropical 
sprue and Crohn's disease of the ileum, all result in vitamin B12 malabsorption which is 
due to the loss of absorptive surface (Schjonsby, 1989). 
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1.5. Vitamin B12 deficiency; the prevalence, causes and symptoms: 
  
Our search for sources that may provide us with complete information about the exact 
prevalence of vitamin B12 deficiency here in Palestine was failed. The only source was the 
thesis of Amani Ghaleb Mahmoud Yasin submitted for Master Degree in An-Najah 
University. This thesis showed that 43.3% of boys and 44.8% of girls among the age of 10-
18 years have vitamin B12 level of < 200 pg/mL. However, only 10 of those have MCV 
level > 92 fl indicating that 94.4% of those with vitamin B12 level < 200 pg/mL cannot be 
considered having vitamin B12 deficiency, especially since the analysis of the attached 
questionnaire showed that they had no symptoms associated with vitamin B12 deficiency. 
The results of this study spot light the importance for a wide investigation of normal 
vitamin B12 level among Palestinian adolescents (Yasin, 2009). This thesis actually could 
be misleading somehow; because the presence of a relation between hematological 
abnormalities and neurological disease in vitamin B12 deficiency is not must, meaning that 
more than one quarter of patients with neurological manifestations of vitamin B12 
deficiency have either a normal hematocrit or a normal mean corpuscular volume (MCV), 
or even the both may be normal. Also, mean corpuscular volume (MCV) as a diagnostic 
tool for vitamin B12 deficiency lacks specificity since other causes for megaloblastic 
disorder rather than vitamin B12 deficiency presents. Also, in patients with either vitamin 
B12 or folate deficiency, the MCV tends to increase. In addition, if concurrent iron 
deficiency or thalassemia presents the MCV remains within the reference (Snow, 1999). 
 
The true prevalence of vitamin B12 deficiency in the general population is unknown. The 
incidence appears to increase with age. Some mentions that 15 % of adults older than 65 
years had laboratory evidence of vitamin B12 deficiency which could be due to the use of 
gastric acid–blocking agents (Oh and Brown, 2003). Several studies aimed to estimate the 
prevalence of vitamin B12 deficiency in specific groups of people. Pflipsen et al. (2004) 
studied the prevalence of vitamin B12 deficiency in type 2 diabetic patients and found that 
22% prevalence of metabolically confirmed B12 deficiency presents in the primary care 
type 2 diabetic population. Pflipsen et al.(2004) re-back their study results to this specific 
group of patients taking of Metformin which may contribute to vitamin B12 deficiency . 
Another specific group of patients was those patients under a continuously treatment for 
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Phenylketonuria (PKU). The work of studying the prevalence of functional vitamin B12 
deficiency in PKU patients has been taken by Vugteveen et al. They found that vitamin 
B12 concentration within the reference range does not automatically imply a sufficient 
vitamin B12 status in their study group (Vugteveen et al., 2010). 
 
As previously mentioned, the incidence of vitamin B12 deficiency appears to increase with 
age. It has been shown in elderly people, the prevalence of atrophic gastritis ranges from 
20% to 50%. Gastric atrophy is a possible cause, but only in the most severe cases of 
gastric atrophy the intrinsic factor secretion decreases. Nevertheless, atrophic gastritis has 
been reported to cause impaired release of vitamin B12 from food proteins and peptides 
due to impaired acid secretion and reduced digestion by pepsin. Keeping in mind, the 
effect of atrophic gastritis on bacterial overgrowth in the stomach and proximal small 
bowel, which may also reduce the available amount of vitamin B12 via consumption 
(Selhub et al., 2000). 
 
 Another cause for vitamin B12 deficiency is the nutritional deficiency. Normally, human 
storage of vitamin B12 is sufficient for at least two years, but in the case of severe 
malabsorption especially in elderly, vitamin B12 deficiency could be progressed. Other 
causes include chronic alcoholics, the strict vegetarians (Oh and Brown, 2003), or even 
some medications that interfere with gastric acid secretion such as H2-histamine receptor 
blockers or proton pump inhibitors (Koury and Ponka, 2004). 
 
Deficiency of vitamin B12 can lead to a wide spectrum of hematological and 
neuropsychiatric disorders that can often be reversed by early diagnosis and prompt 
treatment. Vitamin B12 deficiency is associated with macrocytic (megaloblastic) anemia, 
and in advanced cases of deficiency, pancytopenia. Neurologic sequencing from vitamin 
B12 deficiency includes paresthesias, peripheral neuropathy, irritability, personality 
change, mild memory impairment and depression (Oh and Brown, 2003). When listing the 
consequences of vitamin B12 deficiency, one cannot ignore the effect of increase 
hemocystein level as a result of both folate and vitamin B12 deficiency which increase the 
risk for thrombosis (Lewis et al., 2006). 
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Functional vitamin B12 deficiency defined as high methylmalonic acid [MMA] values 
despite normal serum vitamin B12 levels. In other words, functional vitamin B12 
deficiency was defined as MMA values >250 nmol/L with vitamin B12 levels >400 
pg/mL. This is common condition, has to be remembered when talking about vitamin B12 
deficiency (Vugteveen et al., 2010). 
 
1. 6. Vitamin B12; the physiology. 
 
Animals and humans both requires vitamin B12 as an essential element in their diet, 
although it is required in small quantities, vitamin B12 is essential for DNA synthesis, 
RNA synthesis ,for fatty acids metabolism, and for other metabolic path ways. It is needed 
as cofactor for only two enzymes in animals and humans; methylmalonyl- CoA mutase 
(adenosylcobalamin- dependent) and methionine synthase (Methylcobalamin-dependent 
enzyme), the crystal structures of them have been solved in 1996 and 1994, respectively 
(Martens et al., 2002). 
 
Methylmalonyl-CoA mutase is involved in the metabolism of propionyl-CoA, which in 
turn derived from the degradation of compounds like thymine, valine, methionine and odd-
chain fatty acids. Propionyl-CoA is carboxylated to form (S) - methylmalonyl-CoA. Here 
the turn of methylmalonyl-CoA mutase starts, this enzyme is responsible about the 
rearrangement of (S) - methylmalonyl-CoA to succinyl-CoA, which ends up in the 
tricarboxylic acid cycle. In vitamin B12-deficiency cases, the methylmalonyl-CoA 
accumulates and then cleaved to coenzyme A and methylmalonic acid, which in turn leads 
to acidosis. Propionyl-CoA also accumulates until citrate synthase condenses it with 
oxaloacetic acid to 2-methylcitric acid (Martens et al., 2002). 
 
The other cobalamin / folate dependent enzyme is methionine synthase, which methylates 
homocysteine to form methionine, which in turn utilizing 5-methyltetrahydrofolate as 
methyl donor. Despite the needs of this enzyme to cobalamin as essential cofactor, normal 
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methionine concentrations are maintained in vitamin B12 deficient patients because high 
folic acid level masks low vitamin B12 level (Martens et al., 2002). 
 
As previously mentioned, cobalamin and folate deficiency are mainly associated with 
hematological abnormalities; one of the hematological abnormality features is anemia. The 
question is how the cobalamin and folate deficiency leads to anemia? Erythropoiesis is the 
process by which the hematopoietic tissue of the bone marrow produces red blood cells 
(Koury and Ponka, 2004).  
 
Erythropoiesis required the presences of several nutrients such as; folate, vitamin B12, and 
iron. This process is forced by many bio-signals, in order to produce sufficient and normal 
red blood cells (RBCs) capable to appropriately do their functions. RBCs functions could 
be summarized in   transporting carbon dioxide and nitric oxide, and to deliver oxygen 
from the lungs to the other tissues of the body. Sufficient and normally function red blood 
cells is as important as having normal lifespan (about 120 day) according to RBCs, 
otherwise hemolytic anemia will results. Hemolysis or bleeding makes a pressure on 
hematopoietic stem cells to exceed the rate of erythropoiesis from 200 billion cells per day 
to about one trillion per day (Koury and Ponka, 2004). The production of such huge 
number of cells requires the maintenance of adequate supplies of the nutrients needed. Our 
interest "vitamin B12" delivered to the cells in his active form; holotranscobalamin II 
(vitamin B12–transcobalamin II complex) and enters to the cells via specific receptor 
proteins that are displayed on the surface of many different types of cells, including, of 
course, the hematopoietic tissue (Koury and Ponka, 2004).  
 
An inadequate supply with vitamin B12 to the hematopoietic tissue is responsible about the 
appearance of megaloblastic anemia features. This type of anemia; megaloblastic anemia, 
although affects all hematopoietic lineages, but seems to be most prominent in the 
erythroid lineage. Megaloblastic anemia has common characteristics and features such; 
pancytopenia with macrocytic erythrocytes, hypersegmented neutrophilic granulocytes 
(even with increased lobe size as well as number of nuclear segments (Lewis et al., 2006), 
and reticulocytopenia (Koury and Ponka, 2004).  
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The bone marrow - and occasionally the blood stream (Lewis et al., 2006), has increased 
numbers of large immature-appearing erythroblasts and myeloblasts, which are called 
megaloblasts (Koury and Ponka, 2004). Megaloblasts have a characteristic chromatin 
pattern with immature nucleus for the degree of cytoplasmic haemoglobinization (Lewis et 
al., 2006). 
 
Other hematological and chemical parameters appear include; elevated serum bilirubin, 
lactate dehydrogenase, myeloperoxidase, and increased iron turnover, as result of 
hemolysis (Koury, Ponka, 2004). Mean corpuscular volume (MCV) may increase up to 
130 fl, while the platelet distribution width (PDW) decreases. Blood film preparation is 
important to investigate the following abnormalities; oval macrocytes, poikilocytes, and 
hypersegmentation of neutrophils, Howell–Jolly bodies, basophilic stippling, and platelet 
anisocytosis (Lewis et al., 2006). 
 
Impaired DNA synthesis is the responsible element in the increased hematopoietic cell 
death that characterizes the megaloblastic anemia, especially in such high proliferation rate 
where the erythroid progenitor cells becomes more susceptible to the impaired DNA 
synthesis. In S-phase of the cell cycle, erythroblasts in patients with folate or vitamin B12 
deficiency anemia had no active incorporation of 3H-thymidine into DNA, despite the 
increase in the total DNA content (between 2N and 4N) (Koury and Ponka 2004). 
Experiments aimed to study the percentages of cells in S-phase in bone morrow of vitamin 
B12 or folate deficient patients shows increased percentages of cells in S-phase compared 
to controls, with relatively decreased in the rate of DNA synthesis (Koury and Ponka 
2004). Impaired DNA synthesis result in chromosomal breakage which appears as 
increased in Howell-Jolly bodies (Lewis et al., 2006). 
 
As mentioned above, methylcobalamin is the coenzyme for the vital enzyme methionin 
synthase. This enzyme transfers the methyl group from 5-methyl-tetrahydrofolate (THF) to 
homocysteine, thereby regenerating methionine and tetrahydrofolate (THF). In the 
deficiency cases, where vitamin B12 is not provided in sufficient amounts; there will be an 
accumulation in homocysteine and decrease in the availability of methionine and 
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tetrahydrofolate (THF) (there will be trapping of intracellular folate in the 5-methyl-THF 
form). THF an especially its form (10-formyl-THF) is involving in the synthesis of 
purines. The other important form of THF that involving in the synthesis of thymidylate is 
the 5, 10-methylene-THF. Both purines and thymidylate are important in the synthesis of 
deoxynucleotides. So, the deficiency in them as a result of vitamin B12 or folate deficiency 
will be reflected as decrease in the deoxynucleotide nuclic acid (DNA). This impaired 
DNA synthesis and repair is the cause of cell death.  According to erythropoiesis, 
ineffective erythropoiesis results, where erythroid cells cannot reach maturity and undergo 
apoptosis causing anemia and other hematological abnormalities (Koury and Ponka, 2004).   
 
In one experiment aimed to study the correlation between the impaired DNA synthesis and 
the cellular events ends with apoptosis, it has been noted that proerythroblasts freshly 
isolated from folate-deficient mice and when cultured with erythropoietin under folate-
deficient conditions accumulate in S-phase of the cell cycle, till they will undergo 
apoptosis eventually (Koury and Ponka, 2004). Those cells may be saved from apoptosis if 
sufficient amounts of both thymidine and a purine add to the culture medium in-vitro. In 
conclusion, there are two main causes that contribute to the features of megaloblastic 
anemia; the shift to left occurs in erythroid differentiation stages leading to the 
accumulation of cells in S-phase, and the increased size compared with less immature 
appearance of erythroid cells in the bone marrow (Koury and Ponka, 2004). 
 
Although the erythroid linage is the most affected one, it is not the only affected linage in 
the hematopiosis process in vitamin B12 deficiency. Megaloblastic anemia is also 
associated with qualitative and quantitative abnormalities of developing and mature 
polymorphonuclear (PMN) leukocytes. Such deficiency usually is associated with 
macrocytic PMN precursors and reduced numbers of circulating PMN leukocytes with 
hypersegmented nuclei (Kaplan and Basford, 1976). It has been believed that those 
abnormalities may also be a result of impaired DNA synthesis (Kaplan and Basford, 1976).  
 
Kaplan and Basford, in their experiment tried to find an answer about the presence of any 
relation between this abnormal PMN cells and the function of them. To study the presence 
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of such relation they investigated seven patients; three with folic acid deficiency and four 
with vitamin B12 deficiency. They evaluated the efficiency of phagocytosis, the 
phagocytosis associated activation of the hexose monophosphate shunt (HMPS) and 
microbicidal capacity against Staphylococcus aureus (Kaplan and Basford, 1976). Before 
they illustrate their findings, Kaplan and Basford re-back to the previous work had been 
done. It had been previously noted that leukocyte in vitamin B12 deficiency had impaired 
propionate oxidation to CO2 due to the decrease in methylmalonyl CoA mutase activity; 
even this finding could not investigate the effect of that on the leukocyte function. Another 
work had been demonstrated that animals newborn feed on folate deficient diet were 
susceptible to infections. Kaplan and Basford, had been concluded that” no impairment of 
phagocytosis-associated metabolism or microbicidal activity in the leukocytes of patients 
with folic acid deficiency. Only in four patients with vitamin B12 deficiency a marked 
decrease in the phagocytosis-associated HMPS activation occurs (Kaplan and Basford, 
1976). They also found that this defect has been corrected with therapy (Kaplan and 
Basford, 1976). 
 
There is a certain relation between vitamin B12 deficiency and some neurological 
dysfunction.  It has also been reported that in case of low vitamin B12 and other vitamins 
level, healthy elderly subjects scored poorly on tests of memory and nonverbal abstract 
thinking (Selhub et al., 2000).The possible interpretation of how vitamin B12 deficiency 
left that dangerous effect on the neurological function could be easily understood when 
reviewing the biochemical pathway involved vitamin B12 as a cofactor. 5, 10-
methylenetetrahydrofolate generated mainly from serine used in several reactions leads to 
the production of thymidylate and purines that’s used for nucleic acid synthesis, and also 
of methionine. Methionine used for protein synthesis and biological methylations, and it is 
so important for the brain function. Methionine synthesis by the reduction of 5, 10-
methylenetetrahydrofolate to 5-Methyltetrahydrofolate, this reaction catalyzed by the 
methylenetetrahydrofolate reductase. 5-methyltetrahydrofolate, in turn, act as a substrate to 
methylate homocysteine. This reaction is catalyzed by vitamin B12 dependent enzymes. 
Methionine is also converted to S-adenosylmethionine (SAM) (a universal methyl donor), 
SAM-dependent methylations in the brain results in the production of neurotransmitters, 
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phospholipids, and myelin Such deficiency usually is associated with macrocytic PMN 
precursors and reduced numbers of circulating PMN leukocytes with hypersegmented 
nuclei no impairment of phagocytosis-associated metabolism or microbicidal activity in 
the leukocytes of patients with folic acid deficiency. That could explain the loss of the 
neurocognitive functions in vitamin B12 and folate deficiency. The final thing have to be 
added according to how low vitamin B12 affects the neurocognitive functions is the 
observation that SAM has to be  converted to S-adenosylhomocysteine (SAH) in this 
methylation reactions, which in turn hydrolyzed to homocysteine and adenosine. So, in the 
state of folate or vitamin B12 deficiency, there will be a decrease in methylation of 
homocysteine, which leads to SAH accumulation, which acts as inhibitor for other vital 
SAM- dependent reactions (Selhub et al., 2000).  
 
 1. 7. Vitamin B12 deficiency; diagnosis and treatment. 
 
In megaloblastic anemia, the impaired production of tetrahydrofolate causes a defect in 
DNA synthesis acompanied with normal cytoplasmic component production. This defect 
results in abnormal large cells that characterized this anemia. The presence of unexplained 
anemia, macrocytosis, or neurological disease, turns the eyes toward vitamin B12 
deficiency (Snow, 1999). Other conditions where vitamin B12 deficiency should be 
suspected include; sore tongue, anorexia, and diarrhea. Attention should also be paid to 
patients at risk of developing vitamin B12 deficiency including;  elderly people, 
vegetarians , patients with intestinal diseases, patients with autoimmune disorders such as 
Graves’ disease, thyroiditis, patients receiving proton pump inhibitors, and histamine 
receptor antagonists (Hvas and Nexo, 2006). 
 
The presence of a relation between hematological abnormalities and neurological disease 
in vitamin B12 deficiency is not a must, meaning that more than one quarter of patients 
with neurological manifestations of vitamin B12 deficiency have either a normal 
hematocrit or a normal mean corpuscular volume (MCV), or even the both may be normal 
(Snow, 1999). 
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Also, the presence of macrocytic red cells is not an exclusive feature for vitamin B12 
deficiency. Macrocytosis is also seen in myelodysplasia (could be confirmed by the 
presence of hypogranular neutrophils or monocytosis), excess alcohol consumption, 
hypothyroidism, liver disease, aplastic anemia, rare inherited orotic aciduria, or Lesch-
Nyhan syndrome also increased the MCV. In addition, some drugs that interfere with DNA 
synthesis (e.g.; azathioprine, azidothymidine [AZT], or hydroxy-carbamide) may lead to 
macrocytosis and megaloblastic (Lewis et al., 2006). From here, it is become clear that 
accurate and reliable diagnosis for vitamin B12 deficiency is a base where the proper 
treatment lay on.  
  
Complete blood count (CBC), blood film, vitamin B12 assay, antiparietal cell antibodies, 
anti-intrinsic factor antibodies, Schilling test, and the assay of other biomarkers, all of 
these have been considered as diagnostic tools in the journey of vitamin B12 deficiency 
diagnosis. All have drawbacks and benefits, and that’s what will be discussed in the 
following few lines.   
 
Macrocytosis is a term that has been used to describe the condition when MCV is above 
100 fl. This condition may or may not associate with anemia. Megaloblastic disorder is a 
term that has been used to define the presence of morphologic changes in the bone marrow 
that are caused by impaired DNA synthesis. It is usually implies a diagnosis of vitamin 
B12 or folate deficiency. Note that, the term “usually” has been used that’s because in 
some cases the presence of macrocytosis may also be cause by nonmegaloblastic disorder, 
i.e. due to the direct effect of alcohol and chemotherapeutic agents on the bone marrow, or 
due to the effect of some drugs on the synthesis of DNA, or due to the acceleration of 
erythropoiesis caused by hemolysis or hemorrhage (both conditions increase the 
reticulocytes count which in turn will be reflected as elevated MCV), even it could be 
artificial; due to cold agglutination (causes RBCs clumps) or severe hyperglycemia (that 
causes RBCs swelling) (Snow, 1999). 
 
The fact that mean corpuscular volume (MCV) as a diagnostic tool for vitamin B12 
deficiency lacks specificity becomes clear when reviewing the presence of other causes for 
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megaloblastic disorder rather than vitamin B12 deficiency. It also lacks sensitivity; that is, 
in patients with either vitamin B12 or folate deficiency, the MCV tends to increase before 
the hemoglobin level decreases. In addition, if concurrent iron deficiency or thalassemia 
presents the MCV remains within the reference range even when there is biochemical 
evidence of vitamin deficiency (Snow, 1999). 
 
When talking about vitamin B12 diagnosis, examination of the peripheral smear seems a 
helpful tool. Well examination of well prepared smear may provide diagnostic clues as the 
presence of oval macrocytes suggesting a megaloblastic disorder, whereas the presence of 
stomatocytes is significantly more common in patients with macrocytosis caused by 
alcoholism. The presence of hypersegmented neutrophils has been found to be highly 
sensitive and specific for the diagnosis of megaloblastic anemia but not in the mild 
deficiency cases where it becomes neither sensitive nor specific (Snow, 1999). 
 
Serum vitamin B12 level measurement has been used worldwide since the 1950s (Hvas 
and Nexo, 2006). It is the most fabulous test. Varying sensitivity and specificity have been 
reported. Also, different methods have been established. The sensitivity and specificity of 
vitamin B12 level assays will be discussed in chapter 4. 
 
The two metabolic markers methylmalonic Acid (MMA) and homocysteine (tHcy) are 
generally considered more sensitive indicators of vitamin B12 status than are plasma 
vitamin B12 levels (Hvas and Nexo, 2006). They have been used as confirmatory test for 
vitamin B12 status in addition to their role in differentiation of vitamin B12 and folate 
deficiencies. Both metabolite levels increase in vitamin B12 deficiency, whereas, only 
tHcy level would be expected to increase in patients with folate deficiency (Snow, 1999). 
Factors other than vitamin B12 deficiency that may elevate methylmalonic acid include; 
renal insufficiency (modest elevation compared with vitamin B12 deficiency), 
hypovolemia, and inherited metabolic defects. While, antibiotic-related reductions in 
bowel flora may reduce methylmalonic acid. According to homocysteine, folate deficiency 
and pyridoxine deficiency, in addition to renal insufficiency and hypovolemia may elevate 
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it. Because of that, it seems difficult to estimate the specificity of those markers (Snow, 
1999).   
 
The disadvantages of those bio-markers assay have been noticed. A study mention that 
normal plasma vitamin B12 levels as well as normal MMA and tHcy levels were found in 
patients with clinical signs of vitamin B12 deficiency improving after treatment with the 
vitamin. This note should be added to the fact that MMA and tHcy assays are complex, 
and expensive (Hvas and Nexo, 2006). 
 
When vitamin B12 deficiency found to be a result of inadequate production of intrinsic 
factor (IF), as in pernicious anemia patients, the assay of different antibodies may be 
helpful in diagnosis. Antiparietal cell and Anti–intrinsic factor antibodies are two 
examples; antiparietal cell antibodies as a cause of autoimmune gastritis found in about 
85% of pernicious anemia patients. It seems to be nonspecific in pernicious anemia 
diagnosis. In contrast, the anti–IF antibody test is considered a relatively specific one, 
despite having problem concerning its sensitivity; where only half of the patients with 
pernicious anemia have detectable anti-IF antibody (Snow, 1999). 
 
To overcome the limitations of the tests listed above, eyes have to go toward the 
measurement of that fraction of vitamin that could enter the cell (via specific receptors) 
and do the function, rather than the measurement of total plasma vitamin B12 level. This 
active form of vitamin B12 attached to transcobalamin and called holo-transcobalamin 
(holoTC) may be a sensitive marker (Hvas and Nexo, 2006) (Woo et al., 2010). One-
quarter of circulating vitamin B12 binds to transcobalamin (holoTC) and is thereby 
available for the cells of the body while the larger fraction of it binds to haptocorrin (Nexo 
and Hoffmann-Lucke, 2011). In 1980s holo-transcobalamin could only be measured by 
calculation of the difference between vitamin B12 and the fraction of vitamin B12 that was 
not attached to transcobalamin, so, the results was not accurate enough to evaluate this test 
and to compare it with other assays such vitamin B12 plasma level  and other biomarkers 
(Nexo and Hoffmann-Lucke, 2011). Now a day, methods for measuring holoTC have been 
introduced. Actually, three methods for its measurement are present; first, the direct 
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measurement of the complex between transcobalamin and vitamin B12. Second, is 
measurement of vitamin B12 attached to transcobalamin, and the final is the measurement 
of the amount of transcobalamin saturated with vitamin B12. Although these three methods 
give similar results, direct measurement of holoTC complex is preferable since it is more 
practical than the others (Nexo and Hoffmann-Lucke, 2011). It has been shown from the 
evaluation of the available methods that AxSYM holoTC assay is a reliable and 
reproducible technique for the measurement of holoTC levels (Woo et al., 2010). In 
conclusion, if the serum vitamin B12 level is between 151-300 pmol/L, holoTC alone or in 
combination with the serum vitamin B12 is likely to be more useful than serum vitamin 
B12 levels alone to indicate vitamin B12 status (Woo et al., 2010). HoloTC is an early 
marker of vitamin B12 deficiency, but further studies are also needed in order to evaluate it 
(Snow, 1999). 
 
The speech about holoTC never stopped; because of the risky inputs of vitamin B12 
deficiency in old age people. Finding a reliable screening test should take greater interests. 
This facet attracts Clarke group attention. They design a study in order to compare between 
the usage of conventional vitamin B12 assay and the new interest holoTC. Their 
population was composed of 2403 of older people with normal and abnormal renal 
function. Modest superior diagnostic utility of holoTC compared with conventional 
vitamin B12 testing for the detection of vitamin B12 deficiency has been demonstrated. 
This superior diagnostic accuracy of holoTC was also confirmed in two independent 
populations in Oxford, using slightly different assay methods to measure holoTC 
concentrations. They also recommend that neither test can be used to screen asymptomatic 
populations (Clarke et al., 2007) 
 
In its roundtable which took place in July 2010 the National Health and Nutrition 
Examination Survey (NHANES) discussed the potential utility of measuring holoTC for 
future NHANES. In summary, the roundtable experts (23 experts in folate and vitamin B12 
assessment, clinical laboratory science, and biostatistics and 10 scientists from US 
government agencies that generate or use NHANES data and develop reference methods 
and materials for these measures) supported reinstating vitamin B12 related biomarkers in 
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future NHANES. The roundtable also agreed that future NHANES should include at least 
one biomarker of the two circulating vitamin B12 concentrations (they prefer vitamin B12 
rather then holoTC) and one metabolic indicator of vitamin B12 insufficiency (they prefer 
MMA on tHcy) (Yetley et al., 2011). 
 
In order to diagnose whether the vitamin deficiency is caused by lack of intrinsic factor, 
Shilling’s test has been introduced. In this test labeled vitamin B12 has to be administered 
orally alone (Shilling’s test I) or together with intrinsic factor (Shilling’s test II).With the 
development of advanced techniques such as acceleration mass spectrometry, theoretically 
feasible vitamin B12 absorption test is recently described. Here, acceleration mass 
spectrometry is used to assess the absorption and kinetics of carbon-14-labeled vitamin 
B12 (Hvas and Nexo, 2006). One of the disadvantages of Shilling’s test is the difficulties 
in its procedure concerning the use of radioactives. This encourages Anne-Mette Hvas and 
Ebba Nexo to develop an alternative approach to measuring vitamin B12 absorption, 
named CobaSorb. This test depends on the oral administration of non-radioactive vitamin 
B12, followed by the measuring of active vitamin B12 (holoTC) absorption. When no 
increase in active vitamin B12 detected this indicates the presence of Imerslund Grasbecks 
syndrome or inherited lack of intrinsic factor. For wider applications, this CobaSorb needs 
wider evaluation (Hvas and Nexo, 2006). 
 
From the above discussion, one can notice the difficulties in diagnosis of vitamin B12 
deficiency. When it is being diagnosed, vitamin B12 deficiency, have to be probably 
treated to overcome the very bad inputs of deficiency. When malabsorption has not been 
the ultimate cause for the deficiency, the case easily treated by the daily supplement in the 
form of a vitamin pills. Forms of vitamin B12 supplements includes; cyanocobalamin, 
hydroxycobalamin, and methylcobalamin. Cyanocobalamin is the only form available in 
the USA, although hydroxycobalaminmay has advantages due to a slower metabolism. 
Another route for vitamin B12 administration, rather than the oral route, also presents. 
Intramuscular injections in the form of cyanocobalamin or hydroxycobalamin vary 
according to the countries strategies. In the USA the usual treatment regime is injections 
with a daily dose of 1000 µg cyanocobalamin for the first week followed by weekly 
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injections for the next month and after that monthly injections used (Hvas and Nexo, 
2006). 
 
According to the oral administration, a daily oral dose of at least 1000 µg of vitamin B12 
should be sufficient to maintain a normal vitamin B12 level to overcome the hematological 
manifestations of vitamin B12 deficiency. But, these doses are not so effective in giving 
that desirable benefit in case of severe neurological manifestations. Assistant treatments 
includes; iron supplements (because when red cell production increase the demand on iron 
stores also increase) and folate supplements (to correct the situation where folate 
deficiency has been masked by vitamin B12 deficiency) (Hvas and Nexo, 2006). 
Monitoring the treatment divided into two branches; the first, hematological monitoring 
includes; reticulocytes (after 1 week) and hemoglobin (after 1 to 2 months). The second 
monitoring branch is the biochemical monitoring which is not needed in patients receiving 
intramuscular injection treatment, only in patients given oral vitamin B12, plasma 
cobalamins, MMA or tHcy should be assayed to monitor the response to the treatment 
(Hvas and Nexo, 2006). 
 
1.8. Vitamin B12 deficiency; the available methods for analysis.  
 
Accurately quantifying vitamin B12 has been considered a challenge. Because the daily 
requirement of vitamin B12 is as low as 1 to 3 micrograms, the deficiency may be at the 
nanogram to picogram level; this fact is what makes the quantification process as difficult 
as it (Kumar et al., 2010). Different methods have been established to measure vitamin 
B12 in different components such as; serum, food and supplements, and microbial broth. 
Methods used frequently for vitamin B12 determination include microbiological assay that 
uses Lactobacillus leichmannii as the test organism, radioisotopic assay, high-performance 
liquid chromatography (HPLC), chemiluminescence (CL) assay, fluorimetric assay, 
capillary electrophoresis (CE), matrix-assisted laser desorption/ionization (MALDI), time-
of-flight mass spectrometry (TOFMS), and atomic absorption spectrometry (AAS) (Kumar 
et al., 2010). Not all of those methods could be used for the determination of the clinical 
samples. In addition, not all are practical for the routine analysis. In the following few lines 
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the available methods for determination of vitamin B12 in the clinical samples will be 
discussed, and the advantages and disadvantages of each method will be highlighted.  
  
Prior to any analysis procedure, the extraction step is important in order to extract vitamin 
B12 from its binding proteins. This extraction step could easily be done by denaturing the 
protein either by ultraviolet (UV)–visible light, heat, and/ or in alkaline conditions. It is 
also important to convert the light sensitive forms into more stable CN-Cbl form by 
exposing it to dilute cyanide solutions (Kumar et al., 2010). Measuring the activity of 
vitamin B12 differs from the quantification of it. The activity has been measured through 
the assessment of macrocytic anemia improvements, Hcy reduction, and MMA reduction 
(Kumar et al., 2010).  
 
The microbiological assay is the first traditional method that has been used to quantify 
vitamin B12. It is based on Shorb observation in 1947; he noted that Lactobacillus lactis 
would not grow in vitamin B12 free medium. The method found to be unreliable for 
measuring the vitamin B12 content of plants which often contains vitamin B12 analogs. In 
addition, it has been considered as a time-consuming, nonspecific, and gives low values in 
the presence of antibiotics or cytotoxic drugs (Kumar et al., 2010; Ruff, 1979). Hence, the 
search for another method to overcome the disadvantages of the microbiological assay has 
been succeeded in the development of a method that has been considered as; simple, 
readily available in the form of commercial kits, specific, sensitive, and not influenced by 
antibiotics. It is the radioisotopic dilution assay which is based on the competition between 
vitamin B12 in the solution being assayed and a known amount of 57Co-labeled vitamin 
B12 for the vitamin B12 binding sites on a protein such as IF or R-protein. One cannot 
ignore the false normal values have been taken using the radioisotopic dilution assay, 
which was due to the non pure IFs have been incorporated in the commercial kits. The 
presence of R- proteins in those kits also binds the vitamin B12 analogs and falsely 
elevates the results (Kumar et al., 2010; Ruff, 1979).   
 
In 1965, relatively similar method with some developments has been described. In this 
method, unlabelled vitamin B12 released from serum and diluted with a known quantity of 
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57CoB12, then bound to intrinsic factor which, having a B12-binding capacity less than 
the amount of added 57CoB12. Intrinsic factor becomes saturated with the B12 mixture. 
Unbound B12 is removed by absorption onto protein-coated charcoal and the degree of 
dilution of the radioactive B12 is proportional to the amount of unlabelled B12 (Raven et 
al., 1966). Raven has compared the results of microbiological procedure (L. leichmannii) 
with the new method; he found that this method appears to be as sensitive and reliable as 
microbiological assays for measuring vitamin B12 (Raven et al., 1966).   
 
Chromatographic methods is not a determination method by itself, rather, it is a separation 
method that must be combined to another detection method in order to quantify the 
separated molecules. So, the precision and accuracy of the methods depend on the 
detection method. Thin layer chromatography (TLC), gas–liquid chromatography (GLC), 
HPLC, or Gas chromatography, all may combined to mass spectrometry, fluorescence and 
electrochemical detection or other detectors. Even UV visible light may be the detection 
method such in  isocratic or gradient elution UV–visible reverse phase HPLC which has 
been used for determination of vitamin B12. UV detection is not sensitive and the use mass 
spectrometry method or other detection methods is expensive and time consuming (Kumar 
et al., 2010). 
 
Chemiluminescence (CL) is defined as processes that result in the emission of light due to 
chemical reactions. A fully automated CL analyzer (Chiron Diagnostics, Erst Walpole, 
MA, USA) for the determination of vitamin B12 in serum has been used. Good linearity 
and sensitivity for this method has been reported, whereas specificity is still questionable 
(Kumar et al., 2010). 
 
Enzyme-linked immunosorbent assay is the new track that has been developed in order to 
overcome the drawbacks of the other methods and as achievement for the continuous 
researches aimed to develop rapid and specific methods for detection of total vitamin B12. 
Immuno-based methods could be divided into two procedures; those using antibodies 
antigen reaction such as radioimmunoassay [RIA] and enzyme-linked immunosorbent 
assay ELISA),  and those using natural vitamin binding proteins with either radiolabels (as 
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in radiolabeled protein binding assay [RPBA]) or enzyme labels (as in enzyme protein 
binding assay EPBA) (Kumar et al.,  2010). 
 
The indirect type of ELISA is the type commonly used for vitamins; where vitamin (from 
the sample) and protein conjugate (IF or R-protein) are immobilized on the surface. 
Labeled binding proteins have to be added; which may be conjugated to horseradish 
peroxidase (HRP). R-protein was labeled with HRP. Another procedure has been described 
by Tsalta and coworkers in 1989 based on the competition between the analyte and 
glucose-6-phosphate dehydrogenase– vitamin B12 conjugate for a limited number of R-
protein binding sites immobilized on Sepharose particles. The procedure farther improved 
and sample pretreatment with denaturing agents was described by Watkins and coworkers 
in 1992 (Kumar et al., 2010). 
 
The competitive binding assay is the method on which the four automated analyzers used 
in this study rely. The general assay steps and the differences between the analyzers will be 
discussed in the following chapter.   
 
1.9. Literature review for vitamin B12 measurement:  
 
As the first line screening test for vitamin B12 deficiency, attention has been paid to serum 
vitamin B12 assay. Because there are different methods for analysis, different pretreatment 
steps, and different automated analyzers have been developed. The investigation of the 
agreement between these widely used fully automated vitamin B12 assays is must. The 
previous work of Michael Vogeser and Stefan Lorenzl in 2007 aimed to investigate the 
agreement between three of these widely used fully automated vitamin B12 assays. For 
this purpose; aliquots of 100 samples which were left after requested cobalamin 
determination have been frozen, then analyzed using the three investigated systems. Data 
has been collected and regression analysis has been performed according to Passing and 
Bablock (Vogeser and Lorenzl, 2007). 
 
Here is the difference; Michael Vogeser and Stefan Lorenzl compared the systems of; 
Abbott Architect B12 (Abbott, Abbott Park, USA), ADVIA Centaur VB12 (Bayer 
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Healthcare, Fernwald, Germany) and Roche Cobas Vitamin B12 (Roche Diagnsotics 
GmbH, Mannheim, Germany) (Vogeser and Lorenzl, 2007). Since those are not the 
commonly used analyzers in our country, different systems “analyzers” would be included 
in our study. 
 
Vogeser and Lorenzl results showed a rather good numeric correlation between serum 
cobalamin results obtained with three fully automated methods, but a difference of 16% in 
the mean concentration of the lowest reading, and the highest reading. Vogeser and 
Lorenzl also paid some attention to number of samples analyzed in two analytical batches 
in one laboratory. They noticed that among-laboratory differences may be even more 
pronounced (Vogeser and Lorenzl, 2007). 
 
A wider study also has been done by Hendriks et al. in 2000. They evaluated the analytical 
performance of the new generation immunoassay analyzers (ACS:Centaur®, Architect 
TMi2000, Elecsys®2010, Immulite®2000 and Vitros ECi) for the following analytes: 
TSH, FT4, vitamin B12, ferritin, folate, CEA, HCG, PSA, estradiol, LH, FSH, prolactin, 
and progesterone. Their results showed that the within-run precision of the test results for 
most assays was good, and for some assays on the Vitros ECi (HCG, PSA, FSH and 
prolactin) and Elecsys 2010 (FT4, FSH and prolactin) even very good precision (< 2%) has 
been measured. They also observed a relatively higher CV’s for the anemia assays (ferritin, 
vitamin B12 and folate), on the ACS:Centaur and the Immulite 2000. They also found no 
sample carry-over for any of the analyzers. Most methods showed good correlation 
(r>0.97). Significant intercept differences were measured for the prolactin assay on the 
Vitros ECi and the vitamin B12 assay on the Elecsys 2010 (Hendriks et al., 2000). 
In 2010, another work for Badiou S. et al. compared the radioimmunoassay (RIA) 
(Simultrac, Diasorin, Italy) method for vitamin B12 assay with the immunoenzymatic 
method (IEA) using Access 2 (Beckman Coulter, France). They found relatively good 
performance for the automated immunoenzymatic machines. Comparison of RIA and 
IEA on the Access2 using EDTA samples showed a discrepancy for B12 (y = 0.67x + 
211; r = 0.37). This discordance for vitamin B12 was not observed when comparing 
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RIA and IEA on the Architect i2000 (y = 0.74x + 40; r = 0.92) and disappeared when 
using heparinized samples for the Access2 (y = 0.85x + 7.05; r = 0.90).They concluded 
that automated IEA may be a good alternative to RIA for the determination of folate 
and vitamin B12 (Badiou et al., 2010).  
Steijns et al. in 1996 evaluated of the microparticle enzyme immunoassay for 
estimating vitamin B12 in serum. The assays have been performed with the Abbott 
IMx analyzer. Intra-assay coefficients of variation have been found to be from 3.4% to 
8.0% for vitamin B12. Linearity has been considered satisfactory, with an analytical 
recovery of 119 +/- 4% for vitamin B12. The detection limit was 56.2 pmol/L for 
vitamin B12 (Steijns et al., 1996). 
Assay for vitamin B12 on the Abbott AxSYM Analyzer first developed and evaluated in 
1999. For method comparison, this assay has been compared with three existent methods; 
IMx B12 (Abbott Laboratories), Quantaphase B12 (Bio-Rad Laboratories), and ACS: 180 
B12 (Chiron). They concluded that the AxSYM B12 assay is sensitive and precise, and its 
results correlate well with that of a manual isotopic method also (Wilson et al., 1999). 
 
Actually, there is no reference method for vitamin B12 determination. For many years the 
microbiological assay using Euglena gracilis or Lactobacillus leichmannii, were used in 
both routine and reference laboratories (Mollin et al., 1980). The complexity of the 
microbiological assay encourages the use of the newly introduced, that time, radioisotope 
dilution (RID) assays, not only because it is available in the form of commercial kits, but 
also because its providing rapid results, and, in contrast to the microbiological assay, and 
not being affected by antibiotic or other drugs in serum (Mollin et al., 1980). Mollin et al 
reported in their paper the results of interlaboratory trials of serum and plasma vitamin B12 
assay carried out in the United Kingdom by participants in the National Haematology 
Quality Control Scheme (Mollin et al., 1980).  The interlaboratory trials results have been 
compared of microbiological and radioisotope dilution (RID) assay of serum vitamin B12 
in Britain. Wide variation between the L. leichmannii microbiological assay and the RID 
methods has been observed, RID gave higher results than microbiological assay (Mollin et 
al., 1980). In addition, the development of a (mass spectrometric) reference method for 
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vitamin B12 is hardly possible due to its complexity, cost, and its need for trained 
technicians (Vogeser and Lorenzl, 2007).   
 
1.10. Problem statement. 
 
Although there is some limitations according to its sensitivity and its specificity (Lewis et 
al., 2006), total serum vitamin B12 assay still the first test to be done in vitamin B12 status 
investigation in many laboratories. It is considered as a screening test not only to 
investigate megaloblastic anemia but also because neuropathy and neuropsychiatric 
changes may occur also in vitamin B12 deficiency in the absence of macrocytosis or anemia 
(Lewis et al., 2006). Many reports have discussed the role of increased plasma 
homocysteine and serum methylmalonic acid (MMA) levels as indicators for vitamin B12 
deficiency. Although they are helpful in vitamin B12 status investigation, those biomarkers 
are technically difficult in measurement and so are not routine in many laboratories, 
especially here in Palestine where possibilities are limited.  
 
Starting from the point that total serum B12 assay is an important screening tool, and from 
our knowledge about the huge number of vitamin B12 requests received yearly, and from 
the notice that the number of requests are consequently increased (in some countries there 
is up to 72% increased in vitamin B12 requests between 2003-2008 (McHugh et al., 
2012)), one can understand the importance of obtaining an accurate results considering 
vitamin B12 tests. In addition, during the last several years the number of vitamin B12 
requests increased progressively in the West Bank (personal communication) and vitamin 
B12 deficiency become a dogma among Palestinian.            
 
1. 11. Justifications. 
 
This study is designed to compare the results of total serum vitamin B12 obtained from 
four different widely used automated analyzers in West Bank, this will be the first such 
study done in Palestine and the first comparison between those four automated analyzers. 
When comparing the results of those analyzers we actually compare between the different 
methods, although all are based on immunoassay method but some differences in the assay 
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steps are present. This study will also help in establishing a clear relation between the 
different methods used and the results obtained, which in turn will help in answering the 
questions about the relation between the method used in the assay and the results obtained. 
In other words; the presence or absence of a difference between the results obtained will 
illustrates the differences exist in the patients results. Never forget that the results of this 
study will be helpful in assessing the agreement and harmony between laboratories 
concerning serum vitamin B12 results.   
 
1.12. Goals.  
 
Two main factors contribute to the progressing of immunoassay testing over years. One is 
the introduction of several alternatives to the radioimmunoassay which are less hazardous 
detecting labels, with the improvement in antibody production methods have been taken 
place. The other is, the improvement in the automation which further increase the 
reproducibility and sensitivity and shorting the reaction times. (Hendriks et al., 2000) 
 
The purpose of this study is to compare the results of total serum B12 obtained from four 
different widely used automated analyzers in West Bank, the repeating of a serum sample 
assay 10 times will be helpful in the assessment of the within-run precision for those 
analyzers. Another important part and the core of this study is the method comparison part, 
where we will calculate the correlation coefficient for this purpose and investigate the 
agreement level between the methods. If these methods do not match or agree, this will 
support the claim of Younis (Younis, 2010) that vitamin B12 assay is highly variable 
among laboratories in the West Bank.  
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Chapter Two: Materials and Methods  
 
2.1. Materials used in this study. 
 
The materials that were used in phlebotomy and in aliquots preparation are shown in Table 
(2.1). 
 
Table 2.1: Materials used in the study. 
 
Item Trade mark 
23G Needles BD Microlance 
Tourniquet -------------------- 
7 ml plain tubes “vacuum tubes” AFCO 
70 % methyl alcohol swabs -------------------- 
Sterile gauze swabs and Adhesive dressings -------------------- 
Rack -------------------- 
1000 μL automatic pipette -------------------- 
5 mL syringes MEDI-PLUS 
Eppendorf tubes -------------------- 
Permanent marker -------------------- 
Centrifuge (Centurion Scientific) Ford Airfeild industrial estate, ford , 
UK 
 
 
2.2. The questionnaire.  
 
A questionnaire has been designed purposefully for this study. It includes personal 
questions about the volunteers participating; such as names, age, and sex, address and 
phone numbers. The volunteers’ health status was also investigated; in terms of previous 
testing for vitamin B12 levels, any current diseases, and any medications administered at 
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the time of the study; including vitamins. The questionnaire has been filled by all the 
participants and each participant signed a consent form. 
 
2.3. Sample collection. 
 
Thirty adult participants aging 17 – 53 years have been randomly chosen. Individuals with 
systemic diseases such as diabetes, hypertension or any cardiovascular diseases were 
excluded. Also, individuals taking any vitamin B12 supplements of any type were also 
excluded. We aimed at choosing donors so that our group of samples may contain different 
levels of vitamin B12; low, normal, and high. This was accomplished by asking the 
participants about any previous results for vitamin B12.  
    
Samples have been collected through vein puncture. Five mL of venous blood has been 
collected from each participant in 7 mL plain tubes. Each sample has taken a number from 
1 to 30.  
 
2.4. Sample preparation.  
 
Samples have been centrifuged at 3000 rpm for 3 minutes within less than one hour of 
phlebotomy and serum has been obtained. Each serum sample was divided (using 1000 μL 
automated pipette) into four aliquots (300 μL each). Serum aliquots were transferred to 
plastic Eppendorf tubes (1 mL volume). Each set of aliquots was given the same number 
that correlates with that given to each sample during collection (from 1 to 30). Aliquots 
were stored at -18°C until analysis. All aliquots were subjected exactly to the same 
handling procedures before analysis by each method. In the analysis day, samples have 
been transported to each laboratory on ice.   
 
2.5. Sample assay.  
 
Serum samples have been run in three different clinical laboratories in Ramallah city on 
four different automated analyzers. The clinical laboratories participated in the study are; 
Horus Specialized Medical Laboratories (assay vitamin B12 on IMMULITE ®1000), 
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Specialized Medical Laboratories (assay vitamin B12 on TOSOH® and ADVIA 
Centaur®), and Ramallah Specialty laboratory (assay vitamin B12 on AxSYM system®).  
 
The laboratories received 30 frozen coded serum samples and a labeled control. Samples 
have been left at room temperature until complete thawing and then well mixed. 
Laboratories were asked to perform vitamin B12 assay on their usual methodology within 
3 hours of samples’ thawing. All handling instructions for the tests given by the respective 
manufacturer have also been followed. We did not repeat any reading and took the first 
measurement by each method to be used in the methods comparison study. 
 
2.6. Repeated measurements. 
 
In order to assess the reproducibility of the analyzers, 15 mL of venous whole blood has 
been collected from three normal individuals using 21 G Becton-Dickinson Vacutainer® 
multiple sample needle. The samples were centrifuged at 3000 rpm for 3 minutes after 
complete clotting (after 15 minutes of drawing) and then, serum was separated and pooled. 
After that, 3 aliquots (2.0 mL each) were prepared from the pooled sample. Aliquots were 
transferred on ice within less than half an hour to the intended laboratories. Aliquots were 
kept refrigerated at 4 -6 Cº until analysis. The serum aliquots were assayed 10 times on 
each analyzer in one run and within 3 hours of drawing and preparation. 
 
Assay has been performed after the acceptance of the control results. All handling 
instructions for the tests given by the respective manufacturer have also been followed. 
Finally, results have been collected and kept for the statistical analyses.   
 
2.7. Assay methodology and principle of determination. 
 
There are currently no internationally recognized reference methods for serum vitamin B12 
measurement. However, the four analyzers to be compared for vitamin B12 assay rely on 
the competitive immunoassay technology. This method involves common steps despite the 
automated analyzer to be used, but different signal detection techniques and pre-treatment 
steps. 
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The 1st step in the assay is the releasing step. In this step vitamin B12 has to be released 
from its endogenous binding proteins (transcobalamins) before measurement. The 
releasing is accomplished by alkaline hydrolysis (NaOH at pH 12–13) or by heat in the 
presence of potassium cyanide (KCN) which converts the cobalamin (vitamin B12) forms 
into the more stable cyancobalamin form. The releasing step reagents also must contain 
dithiothreitol (DTT) which prevents the rebinding of the released vitamin B12.  
 
The 2nd step is the competitive step of the assay in which serum-derived cyancobalamin 
competes with labelled cobalamin (which is usually attached to a chemiluminescent, 
fluorescent substrate or an enzyme) for limited binding sites on porcine intrinsic factor. 
 
The 3rd   step is the separation of bound and unbound vitamin B12 done by a number of 
electro- or physico-chemical and immunological methods. Other differences between the 
four analyzers will be highlighted in the following illustration of the principle of the assay 
for each analyzer.   
 
2.7.1. Principle of the procedure in IMMULITE ®1000. 
 
The vitamin B12 determination using IMMULITE ® 1000 analyzer (Seimens Healthcare 
Diagnostics Products Ltd; Llanberis,UK) is a solid-phase, competitive chemiluminescent 
enzyme immunoassay procedure. IMMULITE vitamin B12 involves a preliminary heat 
denaturation step. Vitamin B12 in the patient sample is released from carrier proteins by 
incubation at 100°C in the presence of dithiothreitol (DTT) and potassium cyanide to 
inactivate vitamin B12-binding proteins, as well as antibodies to intrinsic factor. After the 
heat denaturation step, the treated patient sample and the hog intrinsic factor are 
simultaneously introduced into an IMMULITE test unit containing a polystyrene bead 
coated with a B12 analog, and incubated for approximately 30 minutes at 37°C with 
intermittent agitation. During this incubation, vitamin B12 in the treated sample competes 
with the B12 analog on the solid phase for a limited number of vitamin B12 binding sites 
on the purified intrinsic factor. (Endogenous vitamin B12 analogs do not interfere, because 
the binder is free of R-protein.) Alkaline phosphatase-labeled anti-hog intrinsic factor is 
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introduced, and the test unit is incubated for another 30-minutes cycle. The unbound 
enzyme conjugate is removed by a centrifugal wash, then, a chemiluminescent substrate 
added which produce a detectable signal (product insert). 
 
2.7.2. Principle of the procedure in ADVIA Centaur® System. 
 
In ADVIA Centaur® (Seimens Medical Solutions Diagnostics; Tarrytown, USA) vitamin 
B12 assay is a competitive immunoassay using direct chemiluminescent technology in 
which vitamin B12 from the patient sample competes with vitamin B12 labeled analog 
(labeled with acridinium ester), for a limited amount of purified intrinsic factor. The 
purified intrinsic factors are covalently coupled to paramagnetic particles in the Solid 
Phase. The assay uses releasing reagent which contains sodium hydroxide and DTT to 
release the vitamin B12 from the endogenous binding proteins in the sample. It also 
contains cobinamide to prevent rebinding of vitamin B12 to the binding proteins after the 
addition of the solid phase to the reaction matrix. An inverse relationship exists between 
the vitamin B12 in the sample and the relative light units (RLUs) detected by the system 
(product insert). 
 
2.7.3. Principle of the procedure in Abbott AxSYM system®. 
 
In AxSYM ® (Abbott Ireland Diagnostics Division; Longford CO, Longford, Ireland) 
vitamin B12 determination is based on the Microparticle Enzyme Immunoassay (MEIA) 
technology. The first step in the assay is the pretreatment step in which the denaturant (0.8 
N Sodium Hydroxide with 0.005% Potassium Cyanide) envelopes the vitamin B12.  
 
Then, the anti-intrinsic factor antibodies complexed with intrinsic factor coated 
microparticles are added to the reaction mixture. Then, B12 present in the sample binds to 
the intrinsic factor coated microparticles forming a B12-intrinsic factor-microparticle 
complex. The aliquot of the reaction mixture is then transferred to the matrix cell. The 
microparticles bind irreversibly to the glass fiber matrix. After that, the matrix cell is 
washed to remove materials not bound to the microparticles. The B12- Alkaline 
Phosphatase Conjugate is dispensed onto the matrix cell forming a B12-intrinsic factor 
microparticle conjugate complex. Then the matrix cell is washed to remove unbound 
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conjugate. Finally, the substrate, 4-Methylumb-elliferyl Phosphate is added to the matrix 
cell and the fluorescent product is measured by the MEIA optical assembly (product 
insert). 
 
2.7.4. Principle of the procedure in AIA-PACK B12 (TOSOH®). 
 
The AIA-PACK B12 (TOSHO Corporation; Tokyo, Japan) vitamin B12 assay is a 
competitive enzyme immunoassay, which needs a B12 releasing step. The sample 
pretreatment reagents contain potassium cyanide, sodium hydroxide, and dithiothreitol. 
Vitamin B12 present in the pretreated test sample competes with enzyme- labeled vitamin 
B12 for a limited number of binding sites on a fluorescein labeled porcine intrinsic factor, 
which then binds to anti-FITC (fluorescein isothiocyanate) antibody immobilized on 
magnetic beads. The beads are washed to remove the unbound enzyme labeled vitamin 
B12 and are then incubated with a fluorogenic substrate, 4-methylumb-ellifeeryl phosphate 
(4MUP). The amount of enzyme labeled vitamin B12 that binds to the beads is inversely 
proportional to the vitamin B12 concentration in the test sample. A standard curve using a 
range of known standard concentrations is constructed to calculate the unknown 
concentrations (product inserts).  
 
The main points of difference between the four analyzers are; the main principle, the 
releasing step, and the detection principle. Other differences such as; the sample type, the 
sample volume, and the detection limit, the normal range, the sensitivity of the method and 
the effect of the interference in the sample, if present, are listed in Table 2.2.    
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Table 2.2: Comparison of the four analyzers. 
 
Type of 
analyzer 
Main principle Sample 
type 
Sample 
volume 
(µL) 
Detecti-
on limit 
(pg/ml) 
The 
sensitivity 
(pg/mL) 
The 
normal 
range 
(pg/mL
) 
Interference of  
cobinamide 
(vitamin B12 
analogs) 
 
IMMULIT
E 1000®. 
Solid-phase, 
Competitive 
Chemilumine-
scent enzyme 
Immunoassay. 
Serum  200 µL 125-
1200 
125 174-878 No cross 
reactivity with 
cobinamide even 
at concentration 
as high as 1.800  
ng/mL and 
50.000 ng/mL 
ADVIA® 
Centaur 
System 
Competitive 
Chemilumine-
scent 
Immunoassay 
Serum / 
Plasma  
100 µL 45-2000 45 156-672 No interference 
seen when 20 ng 
of cobinamide 
added 
AxSYM® Microparticle 
Enzyme 
Immunoassay 
Serum / 
Plasma 
210 µL 84-1200 84 208-963 cross reactivity 
was 0.1%  when 9 
ng/mL 
cobinamide added 
AIA-
PACK B12 
(TOSOH
®). 
Competitive 
Enzyme 
Immunoassay 
Serum 100 µL 84-2100 84 100-700 Cross reactivity 
was < 0.1% with 
200 ng/mL 
cobinamide. 
 
2.8. The statistical analysis. 
 
In order to assess the agreement between the results of the four methods, the automated 
machines were divided into 6 pairs and data analysis was done on those pairs. Data were 
analyzed by correlation and regression.  
 
The null hypothesis established in this study suspects the absence of any correlation or 
difference between the values of each pair of the automated analyzers. In other words, the 
study has been designed to test the hypothesis that there is no significant difference or 
correlation between the results of each pair of the automated analyzers at the 0.05 level of 
significance.  
 
Based on Bland and Altman, statistical methods for assessing agreement between two 
methods in clinical measurement starts with plotting data and drawing the regression line, 
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which helps the eye in gauging the degree of agreement between measurements (Bland and 
Altman, 1986). The regression line of two agreed methods should be a straight line, non-
significantly different from the equality line (in the equality line: slope =1, the intercept =0 
and r =1) (Magari, 2002). Accordingly, the next statistical step is the calculation of the 
slope, Y- intercept and the correlation coefficient (r). A slope deviation from 1 indicates 
the presence of proportional difference between the two methods. The value of Y-intercept 
indicates the presence of constant bias (difference between the two methods). The 
correlation coefficient (r) will be helpful in estimating the strength of a relation between 
two methods, and not the agreement between them. 
 
For a method or a machine to replace another, three conditions should be met: r >0.95, 
slope of the regression line should be between 0.9 and 1.1, and Y- intercept should be close 
to Zero (Snyder and Larsen, 1983). Depending on that, the comparative pairs’ results were 
assessed and the agreement between them was checked according to this criteria.    
   
To assess the significant of the difference between the methods at the predetermined 
significant level (α=0.05) data was analyzed using SPSS. The probability (P- values) has 
been calculated. The null hypothesis will be rejected if the value of the probability (P- 
value) for each pair equals or is less than 0.05. A larger P-value suggests that there is no 
significant difference between the results of the two comparative analyzers. In other words, 
if the P- value is greater than 0.05 then the null hypothesis would be accepted. 
 
To examine the reproducibility or the precision of the methods, the same pooled serum 
sample was repeated 10 times on the four machines. The mean and standard deviation (SD) 
were calculated for each method. On the other hand, the following formula was used to 
calculate the coefficient of variation (CV) for each machine, and compared with that 
claimed by the manufacturer; evaluating thereby the precision of the machines: 
Coefficient of variation (CV) = Standard deviation*100% 
                                                            Mean 
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Chapter Three: Results  
 
3.1. Questionnaire results.  
 
This study was designed to assess the agreement in the results of the four commonly used 
analyzers for serum vitamin B12 assay in Palestine. For this purpose, 30 participants 
donated their blood samples and 30 serum samples were prepared; each serum sample 
belongs to one participant and took a serial number from 1 to 30. Samples had been tested 
using the four analyzers on the same day (see appendix A). 
 
The participants were 11 males and 19 females. They were considered as the donors for the 
30 blood samples. But only the results of 29 samples have been included in the statistical 
analysis; since one serum sample result was >2000 pg/mL and was therefore excluded, 
because it seems that the relevant participant was taking vitamin B12 supplements.    
 
All the participants were asked to complete the questionnaire prior to blood sampling. The 
questionnaire was designed to collect general information about each one of the 
participants, concerning the age, gender and the general health status of each of them. The 
detailed information about each participant is shown in appendix B. 
    
The percentage of the male participants in the study was 33.3 % compared to 66.7 % 
females. The age of the participants ranged from 17 to 53 years, and the age range of males 
was 23- 53 years, while, the ages range of females were 17- 50 years (Table 3.1). 
Table 3.1: The average age of the participants according to gender. 
 
Gender Number Age range (years) 
Female 18 17-50 
Male 11 23-53 
Total 29 17-53 
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Two of the participants were suffering form joint pain and arthritis and were under 
medications at the time of blood sampling. A third participant was under medication for 
H.pylori at the blood sampling time. Also, one of the participants was suffering from 
personal schizophrenia and has been taking antidepressant drugs for a long period. The rest 
of the participants (87%) did not report taking drugs nor suffering from any mentionable 
diseases.  
 
The participants were asked to mention if they had any of the general symptoms of vitamin 
B12 deficiency at the time of blood sampling. They have been informed about the general 
symptoms of vitamin B12 deficiency which include anemia, paresthesias, peripheral 
neuropathy, irritability, personality change, mild memory impairment and depression. The 
answers came as follows: 22 of the participants (approximately 76%) answered “yes” 
meaning that they had some of these symptoms. Only 7 of the participants were not 
suffering from any of those symptoms. None of the participants in the study were taking 
any form of vitamin B12 supplements during the last three months prior to blood sampling. 
 
3.2. Serum vitamin B12 results.  
 
Thirty samples had been run in three different clinical laboratories in Ramallah city on four 
different automated analyzers; IMMULITE ®1000, TOSOH®, AxSYM system®, and 
ADVIA Centaur® System. Vitamin B12 assays have been performed according to the 
usual methodology, and after the acceptance of the routine quality control procedures. All 
handling instructions for the tests given by the respective manufacturer had also been 
followed.  
 
The first measurement has been taken and used in the methods’ comparison study. One 
sample has been excluded from the data analysis study because its result was very high    
(>2000 pg/mL) and exceeded the upper limit of some machines (participant might be 
taking vitamin supplements). The results of the participants varied widely and included the 
three vitamin B12 concentration levels; low, medium and high (Table 3.2). 
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Eye balling the data, one can see the differences in the serum vitamin B12 results obtained 
from the assay of the same sample on four different machines. As shown in Table 3.2, the 
mean of measurement of vitamin B12 and the CV% for the four  machines (ADVIA, 
TOSOH, IMMULITE, and AxSYM) were 313.9 (40.7), 292.9 (46.7), 351.4  (37.3%), and 
317.7 (37.4%) respectively. Sample number 11 was the only sample with low level of 
vitamin B 12 to agree on by the four machines and samples number 4 and 6 may to some 
extent hold the same impression. Samples number 1, 3, 25, 26, and 27 are low by some of 
the machines and normal by other. Thus, there was no consistency or harmony in vitamin 
B12 results among the four machines. The question now is; to what extent does the results 
of those machines vary? i.e., is the difference between the results of the machines 
significant in the clinical terms to cause a problem in patient’s diagnosis and results 
interpretation? 
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Table 3.2: The results of serum vitamin B12 analysis on IMMULITE ®1000, TOSOH®, 
AxSYM system®, and ADVIA Centaur® System. (Results less than 200 pg/mL were 
bolded). 
 
Sample 
number 
ADVIA ® 
pg/mL 
TOSOH® 
pg/mL 
IMMULITE 
®1000 
pg/mL 
AxSYM® 
pg/mL 
1 191 221 266 253 
2 606 490 546 524 
3 300 196 213 226 
4 160 208 150 207 
5 363 244 352 332 
6 186 196 212 153 
7 312 254 295 314 
8 304 257 373 317 
9 356 426 507 419 
10 635 847 672 701 
11 144 173 150 168 
12 398 485 517 399 
13 340 237 345 319 
14 519 215 273 235 
15 225 206 397 240 
16 225 212 315 287 
17 370 254 439 379 
18 392 283 378 378 
19 252 236 323 269 
20 227 305 349 288 
21 515 415 533 515 
22 260 360 321 324 
23 241 232 268 316 
24 261 301 534 338 
25 381 302 192 175 
26 241 185 207 225 
27 141 212 269 228 
28 309 289 460 398 
29 249 252 335 286 
Mean 313.9 292.9 351.4 317.7 
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3.3 Comparative study.  
 
Results of 29 serum samples for vitamin B12 were available for the method comparison. A 
Pearson’s correlation coefficient (r) was computed to assess the relationship between the 
four machines. There was a positive significant correlation between each pair of the 
machines. With varying degrees of correlation between the comparative pairs, r ranges 
from 0.67 to 0.90. The highest correlation was seen when comparing the results of 
IMMULITE vs. AxSYM results (0.90). Overall, there was a moderately strong, positive 
correlation between each pair of the machines. The P- value was less than the 
predetermined significant level (0.05), and less than 0.001 for all comparative pairs (Table 
3.3). One can conclude that there is a statistically significant positive correlation between 
the methods/machines. However, significant correlation does not mean agreement between 
machines according to Bland and Altman 1986.  
  
The result of the slope also varies, with slopes ranging from 0.69 to 0.81. The y-intercept 
which reflects the constant bias (difference) between the methods also varies widely, with 
values ranging from 32.2 to 134.6. Comparing of ADVIA with IMMULITE yields the 
highest y-intercept value =134.6 (Table 3.3). 
 
Table 3.3: Comparison of 29 samples results for vitamin B12 measured with 4 different 
machines (IMMULITE ®1000, TOSOH®, AxSYM system®, and ADVIA Centaur® 
System).  
 
 
                Comparative pairs 
N slope Y-intercept Correlation 
coefficient 
(r) 
P-
value
Pair 1 ADVIA vs. TOSOH 29 0.78 47.6 0.73 <.001
Pair 2 ADVIA vs. IMMULITE 29 0.69 134.6 0.67 <.001
Pair 3 ADVIA vs. AxSYM 29 0.71 93.8 0.77 <.001
Pair 4 TOSOH vs. IMMULITE 29 0.76 129.9 0.79 <.001
Pair 5 TOSOH vs. AxSYM 29 0.76 96.2 0.88 <.001
Pair 6 IMMULITE vs. AxSYM 29 0.81 32.2 0.90 <.001
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Despite the presence of a significant correlation between all the comparative pairs, none of 
them met the conditions for methods agreement suggested by Snyder and Larsen. The 
three conditions can be summarized as: the correlation coefficient (r) should be > 0.95, the 
slope of the regression line should be between 0.9 and 1.1, and Y intercept should be close 
to Zero. The three conditions should be met in order for a method to replace another 
(Snyder and Larsen, 1983).     
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3.3.1 ADVIA vs. TOSOH.  
 
The ADVIA method had a slope of 0.78 when compared with the TOSOH method. Also, 
comparing of ADVIA with TOSOH yields a y-intercept value equals to 47.6 and r of 0.73. 
The P-value for this comparative pair was less than the predetermined significant level 
(0.05) which suggests the presence of a statistically significant correlation between the two 
methods. 
 
The presence of a correlation between the methods does not mean that they can be used 
interchangeably. In fact, these two methods failed to pass the criteria for agreement 
between methods suggested by Snyder and Larsen.  When comparing ADVIA method vs. 
TOSOH the resulting r of 0.73 is not high enough for the methods to replace one another, 
despite the presence of a significant correlation between them. 
 
The two types of errors; proportional and constant, could be detected when comparing the 
results of ADVIA vs. TOSOH method and are reflected by the results of the slope and y –
intercept respectively. (Fig 3.1) 
 
   
Figure 3.1: Comparison of automated serum vitamin B12 methods: ADVIA vs. TOSOH. 
The solid line is the regression line.  
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3.3.2 ADVIA vs. IMMULITE.  
 
Comparing the results of ADVIA with that of IMMULITE method for vitamin B12 
determination yields the lowest slope ( 0.69) between all of the comparative pairs and the 
highest y-intercept value (y- intercept =134.6), and -as a logical consequence of that- the 
lowest correlation coefficient (r =0.67). This comparative pair actually has the highest 
constant and proportional error among the other comparative pairs (Fig 3.2).     
 
With the low P-value (<0.001), one can infer the existence of a significant correlation 
between ADVIA and IMMULITE methods. But, again this correlation is not enough for 
the ADVIA to replace the IMMULITE according to Snyder criteria (Snyder and Larsen, 
1983). 
 
 
 
Figure 3.2: Comparison of automated serum vitamin B12 methods: ADVIA 
vs.IMMULITE. The solid line is the regression line.  
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3.3.3 ADVIA vs. AxSYM.  
 
This comparative pair of ADVIA and AxSYM yields a moderately strong significant 
correlation. With a slope equals to 0.71, a y- intercept equals to 93.8 and r value equal to 
0.77. However, this comparative pair did not meet the three conditions for methods 
agreement. Although ADVIA and AxSYM has significant correlation between them but 
that was not sufficient for one method to replace another (Fig 3.3). 
 
 
 
Figure 3.3: Comparison of automated serum vitamin B12 methods: ADVIA vs. TOSOH. 
The solid line is the regression line.  
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3.3.4 TOSOH vs. IMMULITE.  
 
Vitamin B12 results of TOSOH compared with that of IMMULITE, the results of this 
comparison did not widely differ from that of the other pair’s comparison. The results of 
this comparison were as follow: the slope of the regression line in this comparison equals 
to 0.76, y-intercept was 129.9 and r was 0.79.  
 
Actually, this comparison has achieved the 2nd highest y- intercept value after ADVIA vs. 
IMMULITE comparison; this high y-intercept result confirms the presence of a relatively 
high constant error between the two methods. The low P-value emphasized the significant 
of this correlation, but, again the strength of this correlation is not sufficient for those 
methods to agree (Fig 3.4).   
 
 
 
Figure 3.4: Comparison of automated serum vitamin B12 methods: TOSOH vs. 
IMMULITE. The solid line is the regression line.  
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3.3.5 TOSOH vs. AxSYM.  
 
The next comparison is the comparison of vitamin B12 results for TOSOH and AxSYM. 
The slope of the regression line of this comparison was 0.76, y- intercept was 96.2 and r 
was 0.88.  
 
The value of r in this correlation was the 2nd highest one. Despite the relatively high 
correlation coefficient value (r), the value of r still not high enough for TOSOH to replace 
AxSYM (Fig 3.5). 
 
 
 
Figure 3.5: Comparison of automated serum vitamin B12 methods: TOSOH vs. AxSYM. 
The solid line is the regression line.  
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3.3.6 IMMULITE vs. AxSYM. 
 
IMMULITE vs. AxSYM results comparison yields the best results between all of the 
comparative pairs for the slope, y- intercept and correlation coefficient (r). The result of the 
slope was 0.81 which was the closer slope result to 1 -between the other pairs- and reflects 
the lowest proportional error between them. 
 
The y- intercept result was also the best among the other pairs, with a y-intercept result 
equals to 32.2 (the closer one to zero among the other pairs). This comparative pair scored 
the lowest constant error. 
 
The r value was also good and equals to 0.90 (the highest r value among the other pairs) 
which represents the strangest correlation. Nevertheless, the relatively good results of this 
comparison did not meet the Snyder and Larsen criteria for those methods to replace one 
another (Fig 3.6).   
   
 
 
Figure 3.6: Comparison of automated serum vitamin B12 methods: IMMULITE vs. 
AxSYM. The solid line is the regression line.  
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3.5 Normal vs. abnormal results.  
 
In order to classify the participants in the study as vitamin B12 deficient or normal, 
according to the results obtained in the study, and considering the lower limit of normal 
vitamin B12 as 200 pg/mL (personal communication with local physicians), five results 
were abnormal with the ADVIA®, three abnormal results with IMMULITE®1000 assay, 
four with the TOSOH® assay, and three with the AxSYM® assay (Table 3.4). However, 
only sample number 11 gave low results of vitamin B12 with the four machines (Table 
3.2). 
 
Table 3.4: Number of abnormal vitamin B12 results in respect to the four different 
machines. 
  
Machine No. of results <200 pg/mL No. of normal results 
ADVIA ® 5 24 
TOSOH® 4 25 
IMMULITE 
®1000 
3 26 
AxSYM® 3 26 
 
The difference is non-significant between the methods when it is due only to the amount of 
measurement imprecision. That’s why imprecision needs to be assessed before any 
agreement testing (Bland and Altman, 1986). 
 
3.6 Repeated measurements.  
Repeatability is relevant to the study of method comparison because the repeatability 
of the methods limit the amount of agreement possible. i.e. if one method has poor 
repeatability, there is considerable variation in repeated measurements on the same 
subject, then the agreement between the two methods is bound to be poor (Bland and 
Altman, 1986). 
Four serum aliquots (2.0 ml each) have been prepared and transferred to the intended 
laboratories. Serum aliquots were assayed 10 times on ADVIA, TOSOH, IMMULITE, 
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and AxSYM analyzers in one run and within 3 hours of sample drawing and serum 
preparation. Assay was performed after the acceptance of the control results. All 
handling instructions for the tests given by the respective manufacturer have also been 
followed. The results of the ten repeated measures are shown in Table 3.5.  
Table 3.5: Repeated measures of vitamin B12 (pg/mL) assayed by the four machines. 
 R 1 R 2 R 3 R 4 R5 R6 R7 R8 R9 R10 
ADVIA 367 362 387 363 343 370 352 365 380 369 
TOSOH 262 283 285 259 242 265 292 279 261 285 
IMMULITE 328 338 312 336 327 319 312 351 330 309 
AxSYM 382 374 386 390 371 387 372 408 391 368 
 
A precision study evaluated the random error by investigating intra-assay repeatability in 
terms of coefficient of variation (CV). The repeatability of a 10-run intra-assay was 
assessed by repeated measurements of one serum sample with 4 different machines. For 
each machine, standard deviation SD and CV was calculated to evaluate precision of the 
machine. Standard deviation for the repeated measures ranged from 12.2 to 15.8, with the 
lowest value for the AxSYM system®, followed by ADVIA ®, followed by IMMULITE 
®1000 System, the highest value was for TOSOH® (Table 3.6).           
 
Table 3.6: Mean, median, standard deviation, and coefficient of variation for the repeated 
measures assay by: IMMULITE ®1000, TOSOH®, AxSYM system®, and ADVIA 
Centaur® System. And the coefficient of variation claimed by the manufactures at three 
vitamin B12 concentration levels; low, medium and high.   
    
Manufacturer CV%  Mean 
(pg/mL) 
Median 
(pg/mL) 
S.D. CV %
At low 
Vit. B12 
conc. 
At 
medium 
vit. B12 
conc. 
At high 
vit. B12 
conc. 
ADVIA 366 463 12.5 3.4 5.0 4.0 2.7 
TOSOH 271 272 15.8 5.8 18.4 9.1 7.0 
IMMULITE 326 328 13.4 4.1 10.3-11.3 5.3 – 6.7 5.9 
AxSYM 382 384 12.2 3.2 6.8- 10.2 3.0 – 5.1 2.9 – 4.9 
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Relatively good precision has been obtained for the four machines that have been 
evaluated.  For the repeated measures, CVs have been compared with that claimed by the 
manufacture at the medium vitamin B12 level since the mean of the repeated measures 
occurs at this range of concentration. As Table 3.6 shows, the CVs of the methods were in 
the range that claimed by the manufacturer or even less than the CV that claimed by the 
manufacturer at the medium vitamin B12 concentration. 
 
 CVs of machines ranged from 3.2 to 5.8, where the lowest value was for AxSYM. 
TOSOH® has the lowest precision among the four machines (CV = 5.8 %), nevertheless, 
its high CV% value still lower than that reported in the manufacture insert. 
 
In conclusion, all the machines have excellent within- run precision for the same sample, 
but results vary widely when measuring the same sample on different machines for vitamin 
B12. 
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Chapter four: Discussion.    
 
In an assay or instrument-validation process, evaluation of the agreement of two or more 
quantitative assays or methods is of essential importance; in order to show that the assays/ 
methods give “equivalent’ results.  Also, in order to exclude the presence of any systematic 
difference between them. The disagreement between methods will cause a problem in 
results interpretation and may be a reason for searching another or a confirmatory test that 
may reflect the patient status best.     
 
For vitamin B12 assay, it is recognized that there is a continuously increase in vitamin B12 
assay requests by physicians. Also physician’s interest in vitamin B12 deficiency status 
increased in the past few years; physicians believed that a low vitamin B12 result is 
responsible for many hematological and neuropsychiatric disorders. They do rely on it in 
the illustration of many patients symptoms (Oh and Brown, 2003). For that reasons, the 
assessment of the four commonly used automated analyzers for vitamin B12 assay via 
assessing the agreement between their results is so important. However, there are currently 
no internationally recognized reference methods for vitamin B12 measurement.   
 
In this study, 29 different serum sample have been done on the IMMULITE ®1000, 
TOSOH®, AxSYM system®, and ADVIA Centaur® System, results have been analyzed 
and compared as mentioned previously.  
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4.1. Method correlation. 
 
This study found a relatively moderate to good numeric correlation between serum vitamin 
B12 results obtained with the four fully automated machines. A positive significant 
correlation (P-value <0.001) with varying degrees of (r) ranging from 0.67 to 0.90 was 
found between each of the comparative pairs. 
 
Overall, the dispersion of data around the regression line was less than desirable. The 
comparison of IMMULITE vs. AxSYM method demonstrated the best overall correlation 
with the comparison method, with the lowest y- intercept (32), and the highest slope and 
correlation coefficient (0.81 and 0.90, respectively). The other comparative pairs showed 
poorer agreement than that seen with IMMULITE vs. AxSYM comparison, with different 
results for slope, y- intercept and correlation coefficient (r). On method comparison 
studies, low correlation coefficient represents random error, differences in slopes are 
suggestive of proportional error, and substantial y-intercepts can be attributed to constant 
error between methods. The comparison of ADVIA vs. IMMULITE shows the highest y- 
intercept (134.6) that reflects the highest constant error, also, the same comparative pair 
shows the highest proportional error and random error (slope=0.69 and r=0.67). The 
correlation between TOSOH and AxSYM shows mainly a constant error with a y- 
intercept equals to 129.9. While the comparison of ADVIA vs. AxSYM shows mainly 
proportional error with slope equals to 0.71.     
 
4.2. Methods agreement. 
 
Despite the presence of a significant correlation between all the comparative pairs, none of 
them meet the conditions for methods agreement suggested by Snyder and Larsen, the 
three conditions can be summarized as: the correlation coefficient (r) should be > 0.95, the 
slope of the regression line should be between 0.9 and 1.1, and y- intercept should be close 
to Zero (Snyder and Larsen, 1983).     
 
Thus; there is no agreement between the methods. The presence of differences between 
IMMULITE and AXSYM assay results could be due to the differences in the pretreatment 
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step (heat vs. alkaline hydrolysis, respectively) and in the assay principle between the two 
assays. Also, the TOSOH method envelope an alkaline hydrolysis step vs. heat in the 
IMMULITE method, this also could be a reason for the significant difference found in the 
results of those two methods. 
 
The variations in vitamin B12 results have been mentioned in many other studies; Michael 
Vogeser and Stefan Lorenzl in their study in 2007 found the same discrepancies in vitamin 
B12 results between the assessed methods. Vogeser and Lorenzl assessed the agreement 
between Abbott Architect Vitamin B12, ADVIA Centaur Vitamin B12, and Roche Cobas 
Vitamin B12. When they applied the expected values of the respective assay, six results 
were sub-normal with the Abbott assay, three with the Bayer assay, and seven with the 
Roche assay. Despite this result variations and diagnosis discrepancy; Vogeser and Lorenzl 
study confirms the close numeric correlation between the vitamin B12 results obtained 
with the three tests studied with Pearson's correlation coefficients between 0.95 and 0.98. 
However, they also observed a relevant systematic bias between the assays (Vogeser and 
Lorenzl, 2007). 
 
4.3. The results discrepancy. 
 
Serum vitamin B12 concentration used to be the first line screening test for the detection of 
vitamin B12 deficiency subjects, but, could the depending on serum vitamin B12 
concentration assay be a problem considering patients diagnosis? The limitation of total 
serum vitamin B12 measurment have been highlighted by studies that showed poor 
specificity of only 50% (i.e. healthy persons with  a low level of vitamin B12 with no 
evidence of deficiency) and sensitivity of 95% (i.e. 5% clinically deficient with normal 
level) (Stabler et al., 1990). Some authors have advocated measurement of MMA and tHcy 
to assist in the assessment of vitamin B12 status (Green, 1995). 
 
This study shows that the diagnosis of the patient as vitamin B12 deficient or normal may 
differ for the same individual depending on the vitamin B12 assay method used. The 
discrepancy in the patients’ classification as vitamin B12 deficient or normal was obvious 
when the number of the deficient vs. normal individual was counted. Considering the 
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lower limit of normal vitamin B12 as 200 pg/mL (personal communication with local 
physicians, 5 results were abnormal when assayed by the ADVIA ® method, 3 with 
IMMULITE ®1000 assay, whereas, 4 with the TOSOH® assay, and 3 with the AxSYM® 
assay. Meaning that, at least five patients whom diagnosed as vitamin B12 deficient by 
ADVIA® assay were misdiagnosed with the other assays.  
 
This discrepancy in the assay results and in patients’ diagnosis may leave its serious 
impacts on patients’ situation causing serious clinical complication. The discrepancy may 
confuse both physician and patient. In view of the lack of specificity and sensitivity of 
vitamin B12 assay and basing the diagnosis of its deficiency solely on laboratory results is 
not straight forward.      
 
4.4. Reasons for results discrepancy. 
 
There are several potential reasons for disagreement between serum vitamin B12 results 
obtained with different methods; differences in the sample pre-treatment steps is one of 
those causes of the results discrepancy (Vogeser and Lorenzl, 2007). Nearly 99% of serum 
B12 is bound to endogenous binding proteins (transcobalamins) and must be released from 
these before measurement (Lewis et al., 2006). Two releasing ways are available: alkaline 
hydrolysis and heat. Usually, in the alkaline hydrolysis NaOH (pH 12–13) used to remove 
vitamin B12 from its binning proteins, the process also required the presence of potassium 
cyanide (KCN) which converts cobalamin to the more stable cyancobalamin and 
dithiothreitol (DTT) to prevent rebinding of released B12 (Lewis et al., 2006). In the four 
automated analyzers used in the study only IMMULITE depends on high temperature (100 
Cº) in proteins denaturation. 
 
The second potential reason for the results discrepancy is the alkaline reaction medium 
result after the first assay step (the alkaline hydrolysis) the alkaline pH may not be optimal 
for the second step with enveloped the binding of the treated vitamin B12 in the serum 
sample with the purified intrinsic factors, so the pH has to be subsequently adjusted to be 
optimal for the binding process (Lewis et al., 2006). 
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Another source of error could be the different binding characteristics of the intrinsic factor 
used for ligand binding, which potentially resulting in different cross reactivity of the 
assays with vitamin B12 analogues formed by the bacterial gut flora (Vogeser and Lorenzl 
2007). Also, vitamin B12 analogues could bind to R proteins (Transcobalamin I or rapid 
protein) if impure sources of intrinsic factor are used in competitive binding assays cause a 
falsely increased vitamin B12 measurements (Klee, 2000). 
 
Since using purified IF enhances the specificity of vitamin B12 immunoassays, 
purification of the IF is important and could be accomplished by: chemical purification of 
porcine IF or by blocking contaminating R proteins by addition of excess blocking 
cobinamide (vitamin B12 analogues). Using Recombinant IF may also be another choice 
and offer enhanced specificity over chemically purified porcine IF. Other assays rely on an 
alkaline denaturation step to inactivate the R proteins. Specificity of pure and blocked IF 
can be demonstrated by the addition of cobinamide to serum. There should be no increase 
in assay value (Lewis et al., 2006). 
 
For the four analyzers used in the study, specificity has been determined and data has been 
given in the product insert of each test.  In IMMULITE the manufacturers claimed the 
absence of any crossreactivity with cobinamide even at concentration as high as 1,800,000 
pg/mL and 50,000,000 pg/mL. Also, the manufacturers of ADVIA mention the absence of 
any crossreactivity with cobinamide when 20ng/mL of cobinamide added to the sera. 
Whereas, AxSYM manufacturers can report a 0.1% crossreactivity when 9 ng/mL 
cobinamide added. Less crossreactivity (<0.1 %) reported in TOSOH with 200 ng/mL 
cobinamide. (Product inserts)  
 
Another potential discrepancy source can be the difference in the signal detection method. 
Chemiluminescent substrate, fluorescent substrate, or enzymes are the different complexes 
generates during the assay process and usually used to produce different signals which in 
turn can be detected and concentration can be calculated (Lewis et al., 2006).  In 
IMMULITE, the substrate adamantyl dioxatane phosphate cleaved by alkaline 
phosphatase–labelled B12-IF complex, resulting in generation of a plateau 
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chemiluminescent signal. In ADVIA Centaur direct chemiluminescent technology is used 
in which vitamin B12 from the patient sample competes with vitamin B12 labeled analog, 
analogs are labeled with acridinium ester and bound to IF coupled to paramagnetic 
particles, photons are emitted in response to pH change. In the Abbott AxSYM the 
substrates 4-methylumbelliferyl phosphate are cleaved by an alkaline phosphatase enzyme 
– vitamin B12 analog complex, and the resulting reaction generates fluorescence. In 
TOSOH method B12 present in the sample competes with enzyme- labeled vitamin B12 
analog for a limited number of binding sites and then incubated with a fluorogenic 
substrate, 4-methylumb-ellifeeryl phosphate (4MUP) (Lewis et al., 2006). 
 
The National Health and Nutrition Examination Survey (NHANES) is a program of studies 
designed to assess the health and nutritional status of adults and children in the United 
States. This organization interested in vitamin B12 levels in populations as an informative 
source about general health status. It is depending on the interpretation of the population 
data after the determination of vitamin B12 levels using different analytical procedures. 
NHANES reported great variability among procedures which was a problem in results 
interpretation. They mention that the absence of a reliable reference material (calibrator) 
and reference analytical method in addition to, the lack of full realization to the modern 
concepts of measurement accuracy and standardization by many health scientists, are 
possible source for the variability (Bock and Eckfeldt, 2011).      
 
For vitamin B12, the methodology of establishing a reference material (based on mass 
spectrometric) is challenging because of the lower concentrations and the complex and 
heterogenous molecular structure of vitamin B12 (Vogeser and Lorenzl, 2007) (Bock and 
Eckfeldt, 2011). The WHO International Reference Reagent 03/178 seems to be the only 
serum derived calibrator in use with a vitamin B12 value assigned by a consensus 
approach (Bock and Eckfeldt, 2011). Lyophelized standards, also, are available from the 
National Institute for Biological Standards and Control (Lewis et al., 2006). The absence 
of such reference material makes it hard to establish a reference method as well (Vogeser 
and Lorenzl, 2007).  
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4.5. The precision. 
 
Pooled serum sample aliquots were assayed 10 times on the four analyzers, and results of 
the 10 repeated measures were collected and analyzed to evaluate the precision of each 
method. The standard deviation of the repeated measures was calculated and ranged from 
12.2 to 15.8. The lowest value was for AxSYM system® followed by IMMULITE ®1000 
System, followed by ADVIA ®, and the highest value was for TOSOH®. 
 
From the standard deviation and the mean results; the coefficient of variation (CV) for 
each method has been calculated. The coefficient of variation (CV) for the methods 
matches with that claimed by the manufactures. Relatively good precision has been 
obtained from the four methods. TOSOH® has the lowest precision (CV = 5.8 %) among 
the four machines. This high CV% for TOSOH® method has been reported in the 
manufacture insert and proven by the repeated measures data analysis in the study. 
AxSYM system® has the lowest CV% value (CV = 3.2%), followed by ADVIA Centaur® 
(CV = 3.4 %) and IMMULITE ®1000 (CV= 4.1 %). In general, the four methods CV% 
was in that range claimed by the manufacturers. 
 
A previous comparative performance assessment of specified methods have shown serum 
B12 intra-method and overall assay coefficients of variation (CV) of 4%–12% and up to 
20% at clinically relevant levels (Lewis et al., 2006).This high CV% was also reported by 
the College of American Pathologist’s Survey K-A summary report in 1999, this survey 
assessed the CVs for six commercial methods for erythrocyte folate and serum vitamin 
B12. Serum vitamin B12 had CVs of 4.4–10.0%; the lowest CV% was obtained by Abbott 
AxSYM and the highest by IMMULITE (Klee, 2000). The mentioned CV obtained by 
AxSYM method (4.4 %) is close to that detected by this study (3.2 %). For IMMULITE 
the situation is different; the College of American Pathologist’s Survey recorded higher 
CV% (10.0%) results for serum vitamin B12 than that obtained by this study (4.1 %)   
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4.6. Vitamin B12 as diagnostic tool. 
 
Early diagnosis of vitamin B12 deficiency is important to prevent progressive, irreversible 
neurological impairment. Delayed diagnosis- and in turn treatment- may lead to 
undesirable consequences. Thus, testing of serum vitamin B12 earned a consequently 
increased interest. With the development of many assays, the need for evaluation of the 
newly introduced and the widely used automated assays was appeared (Solomon, 2005).  
 
Serum vitamin B12 was considered as the first screening test to evaluate the vitamin B12 
status in individuals. Questions about this test as an effective tool in diagnosis have been 
raised. The great variations founded in this and other studies in vitamin B12 results among 
methods and intra laboratories, in addition to, the published researches that discussed the 
analytical issues and limitations of serum vitamin B12 assay, make vitamin B12 assay as a 
diagnostic tool questionable.           
 
Measuring serum vitamin B12 level has been used worldwide since the 1950s (Hvas and 
Nexo 2006). It is the most fabulous test. Varying sensitivity and specificity have been 
reported. The specificity of vitamin B12 assay in general, seems to be limited. It is obvious 
that many patients with low serum B12 levels do not have clinical or subclinical cobalamin 
deficiency (Lewis et al., 2006). In one study, specificity of 60% has been reported when 
considering vitamin B12 level below 200 pg/mL as a predictive level for the deficiency 
status, and 90% specificity when predictive level has been decreased to100 pg/mL (Snow, 
1999). 
 
According to its sensitivity; vitamin B12 assay sensitivity varies between methods. The 
lower limit of detection usually set at about 200 pg/mL (Snow, 1999), whereas, lower 
detection level will increase sensitivity (Lewis et al., 2006). Few factors contribute to this 
variation in the sensitivity of this assay; first, the use of different methods and techniques 
and the absent of reference one and standards, second, the different definition to the 
deficient patients.  
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Sensitivity of 90% to 95% (i.e. 90-95 % of patients have clinical vitamin B12 deficiency 
symptoms with vitamin level below 200 pg/mL) had been estimated when patients 
considered vitamin B12 deficient if they have characteristic clinical features that responded 
to therapy (Snow, 1999). But, when defined the deficient patients as; those having an 
increased in the level of vitamin B12 metabolites, only 50% of the patients have serum 
vitamin B12 level below 200 pg/ml accompanied with increase in the metabolite level 
(Snow, 1999). 
  
Despite its cheapness and the advantage of being an easy performed test (Hvas and Nexo, 
2006), there are several causes for misleading serum vitamin B12 levels; 
myeloproliferative disorders, polycythemia vera, chronic myelogenous leukemia and liver 
disease, all may increase haptocorrin and in turn cause falsely elevated vitamin B12 level. 
In addition, congenital transcobalamin II deficiency and Intestinal bacterial overgrowth 
(due to the production of vitamin analogous) both are additional causes for falsely elevated 
vitamin B12 level. On the other hand, folate deficiency (the relation is not well 
understood), pregnancy, the use of oral contraceptives, congenital deficiency of serum 
haptocorrins and multiple myeloma, all have been considered as falsely lowered vitamin 
B12 level causes (Snow, 1999). 
 
The two metabolic markers methylmalonic Acid (MMA) and homocysteine (tHcy) are 
generally considered more sensitive indicators of vitamin B12 status than are plasma 
vitamin B12 levels (Hvas and Nexo, 2006). They have been used as confirmatory test for 
vitamin B12 status in addition to their role in differentiation of vitamin B12 and folate 
deficiencies (Hvas and Nexo, 2006).  
 
Although there are other causes for their elevation rather than vitamin B12 or folate 
deficiency (Table 4.1) (Snow, 1999), serum MMA and tHcy measurement seems to be 
sensitive for the diagnosis of vitamin B12 deficiency (Snow, 1999). When using a response 
to vitamin B12 therapy as evidence of deficiency, 86% of vitamin B12 responsive patients 
had elevated levels of MMA and 85% had elevated levels of tHcy, whereas, 94% had 
elevated levels of at least one serum metabolite (usually MMA) (Snow, 1999). What also 
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makes those metabolites helpful in vitamin B12 status investigation, is that, the elevation 
in their levels in serum becomes obvious even before the development of hematological 
abnormalities and before the reductions in the serum vitamin B12 level (Snow, 1999).  
 
Table 4.1: Causes for elevation of serum MMA and tHcy. 
 
MMA tHcy 
* Vitamin B12 deficiency 
* Hypovolemia 
* Renal insufficiency 
* Inherited metabolic defects 
* Vitamin B12 deficiency 
* Hypovolemia 
* Renal insufficiency 
* Folate deficiency 
* Hopothyroidism 
* Pyridoxine deficiency 
* Inherited metabolic defects 
* Psoriasis 
 
.  
Snow (Snow 1999) also summaries the performance of the serum metabolites assay in 
patients with clinical defined vitamin B12 or folate deficiency (Table 4.2). 
 
Table 4.2: Performance of the serum metabolites assay in patients with clinical defined 
vitamin B12 or folate deficiency. 
 
% Performance in patients with, 
  
 
Metabolites levels 
Vitamin B12 deficiency         Folate deficiency 
Elevated serum MMA 98 12 
Elevated serum Hcy 96 91 
Elevated serum MMA with 
normal Hcy 
4 2 
Elevated serum Hcy with 
normal MMA 
1 80 
Normal MMA and Hcy 0.2 7 
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Vitamin B12 deficiency diagnosis is not easy and must not rely on serum vitamin B12 
level alone; many strategies and approaches were established to diagnose vitamin B12 
deficiency. Hvas and Nexo confirms vitamin B12 deficiency if vitamin B12 level was 25% 
lower than the bottom reference interval suggested by the manufacturer. They also suggest 
measuring MMA if serum vitamin B12 level was in the gray area (Hvas and Nexo 2006). 
The suggested gray area for serum vitamin B12 level suggested by Hvas and Nexo was 
170-330 pg/mL, in contrast to Snow diagnostic approaches, they do not differentiate 
between patients with hematological abnormalities and those with neurological 
abnormalities. 
 
Two different diagnosis approaches were suggested by Snow; the two approaches differ 
depending on the patient’s signs and symptoms, in other words, they differ if 
hematological or neurological abnormalities appear on the patient. The following 
flowcharts summarize the diagnosis strategies suggested by Snow (Snow 1999).   
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Figure 4.1: Evaluation of the hematological abnormalities suggestive for possible vitamin 
B12 deficiency. MMA indicates methylmalonic acid and Hcy indicates homocysteine. 
Modified from Snow (Snow, 1999). 
 
 
SERUM VITAMIN 
B12 LEVEL 
<100 pg/mL 100-300 pg/mL >300 pg/mL 
Probably vitamin B12 
deficiency 
Assay MMA and Hcy 
Either elevated 
Both normal 
Unlikely vitamin B12 
deficiency 
Vitamin B12 therapy 
Unlikely vitamin B12 
deficiency 
Vitamin B12 therapy 
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Figure 4.2: Evaluation of the neurological abnormalities suggestive for possible vitamin 
B12 deficiency. MMA indicates methylmalonic acid and Hcy indicates homocysteine. 
Modified from Snow (Snow, 1999). 
 
Again and again, it seems very important to us to focus on the absent of gold standards in 
vitamin B12 deficiency assessment. Ralph Green comments on Lawrence R. Solomon 
published article (Solomon, 2005) concerns measurement of vitamin B12, homocysteine, 
and methylmalonic acid. Green has focused on the shocking observation that vitamin B12, 
homocysteine, and methylmalonic acid assay may not be the ultimate “gold standard” for 
diagnosis of vitamin B12 deficiency. He reports that the over-diagnosis of cobalamin 
deficiency is one of the problems, carrying with it the negative consequences of 
unnecessary treatment as well as the cost. Missed diagnosis is the second one, with its 
risky consequences on the neurological functions. Green finally concluded that” the 
currently available assays for identifying or excluding vitamin B12 deficiency, though 
potentially useful, should be used with full awareness of their possible limitations”, and so 
“Nothing gold can stay” (Green, 2005). Since it is difficult to diagnose vitamin B12 
deficiency, researchers recommended clinical evaluation of the treatment response. In 
patients with anemia they recommend monitoring reticulocytes after 1 week of treatment 
SERUM 
VITAMIN B12 
<100 pg/mL 100-300 pg/mL >400 pg/mL 
Probably vitamin 
B12 deficiency 
Assay MMA and 
Hcy 
Either elevated 
Both normal 
Unlikely vitamin 
B12 deficiency 
Vitamin B12 
therapy 
Unlikely vitamin 
B12 deficiency
Vitamin B12 
therapy  
301-400 pg/mL 
Assay MMA 
Elevated 
Vitamin B12 
therapy  
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administration and hemoglobin after 1 to 2 months (Hvas and Nexo, 2006). On the other 
hand, patients with neurological abnormalities due to vitamin B12 deficiency should 
recheck for elevated metabolites levels after 14 day of treatment; if level retain to normal 
then vitamin B12 therapy will be continued, if not, therapy should be discontinued and 
patient should examine for other possible causes for his neurological finding (Snow, 1999).      
 
4.7. Conclusion. 
 
In this study, 29 different serum sample have been tested on the IMMULITE ®1000, 
TOSOH®, AxSYM system®, and ADVIA Centaur® System, results have been analyzed 
and compared.  
 
This study found that the results of vitamin B12 were highly variable among the four 
machines with a relatively moderate to good numeric correlation between serum vitamin 
B12 results obtained with the four fully automated methods. Despite the presence of a 
significant correlation between all the comparative analyzers, none of them meet the 
conditions for methods agreement.  
 
The precision of the compared analyzers (reflected by the coefficient of variation (CV)) 
matches with that claimed by the manufactures. Relatively good precision has been 
obtained from the four methods. TOSOH® has the lowest precision among the four 
machines. 
 
In conclusion, medical technologists need to be aware of the presence of variations in the 
serum vitamin B12 results between different analyzers/ methods. They should start 
measuring the metabolic products tests (mainly MMA) in their routine work and encourage 
physician to request it when serum vitamin B12 result is in the gray area. The second 
message is for physician whom their increased number of requests for serum vitamin B12 
measurement seems to be built on a convenient and traditional work rather than scientific 
evidence. Physician should be familiar with the analytical and technical issues about serum 
vitamin B12 assay. They should request a repeat assay in conjunction with the clinical 
evaluation of the patient and other metabolites assays, if necessary, to make a decision 
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wither to start vitamin B12 treatment or not. An isolated abnormal result of vitamin B12 
should not be the sole criterion on which treatment decisions are made.      
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 .mrof tnesnoc dna eriannoitseuq yduts ehT :A xidneppA
  ﺑﻌﻨﻮاندراﺳﺔ ﺑﺤﺜﻴﺔ 
  :sdohteM tnereffiD yb 21B nimatiV fo tnemerusaeM
 ydutS nosirapmoC A
 enitselaP / knaB tseW
 اﻟﻤﺨﺘﻠﻔѧﺔ   ﺑﺎﺳѧﺘﺨﺪام اﻷﺟﻬѧﺰة21ﺪى اﻟﺘﻮاﻓѧﻖ ﻓѧﻲ ﻧﺘѧﺎﺋﺞ ﻓﺤѧﺺ ﻓﻴﺘѧﺎﻣﻴﻦ ب  ﻣﻌﺮﻓѧﺔ ﻣѧإﻟѧﻰﺗﻬѧﺪف اﻟﺪراﺳѧﺔ 
  ﻣﺸﺎرآﺘﻚ ﺑﻬﺬﻩ اﻟﺪراﺳѧﺔ اﺧﺘﻴﺎرﻳѧﺔ وﻟﻜﻨﻬѧﺎ ﺗﻌѧﻮد ﺑѧﺎﻟﻨﻔﻊ إن,  ﻓﻠﺴﻄﻴﻦ / اﻟﻀﻔﺔ اﻟﻐﺮﺑﻴﺔ واﻷآﺜﺮ اﺳﺘﻌﻤﺎﻻ ﻓﻲ 
  . اﻟﻤﺨﺘﺒﺮات اﻟﻄﺒﻴﺔ أداءﻋﻠﻰ اﻟﺒﺎﺣﺚ وﺗﺴﺎهﻢ ﻓﻲ ﺗﻄﻮﻳﺮ 
  . أﺧﺮىاﺳﺘﻌﻤﺎﻟﻬﺎ ﻷي أﻏﺮاض  ﺳﺮﻳﺔ اﻟﻤﻌﻠﻮﻣﺎت اﻟﺸﺨﺼﻴﺔ ﻣﺤﻔﻮﻇﺔ آﻤﺎ ﻧﻀﻤﻦ ﻟﻚ ﻋﺪم إن
  
  --------------------------------------------------------------------------------------------
          _____________________________________:اﻻﺳﻢ
  __________________________________:رﻗﻢ اﻟﻬﺎﺗﻒ
  __________________________________                              :ﻣﻜﺎن اﻟﺴﻜﻦ
  ___________________:اﻟﺠﻨﺲ
  ___________________ :اﻟﻌﻤﺮ
  
  (ﻻ                             )(ﻧﻌﻢ:                                     )  ﻣﺮضأيهﻞ ﺗﻌﺎﻧﻲ ﻣﻦ 
  
  ______________________________: آﺎﻧﺖ إﺟﺎﺑﺘﻚ ﻧﻌﻢ اﻟﺮﺟﺎء ﺗﻮﺿﻴﺢ ﻣﺮﺿﻚإذا
  
  (ﻻ(                             )ﻧﻌﻢ :                           ) 21B  ﻓﺤﺺ ﻓﻴﺘﺎﻣﻴﻦأﺟﺮﻳﺖ إنهﻞ ﺳﺒﻖ 
  
  _______________________________________ﻣﺎذا آﺎﻧﺖ اﻟﻨﺘﻴﺠﺔ
  
  ( ﻻ(           )ﻧﻌﻢ)ﻓﻘﺮ دم ،ﺿﻌﻒ ﺑﺎﻟﺬاآﺮة،ﺗﻨﻤﻴﻞ ﺑﺎﻷﻃﺮاف،آﺴﻞ وﺿﻌﻒ ﻋﺎم ؟؟        :هﻞ ﻟﺪﻳﻚ أﺣﺪ هﺬﻩ اﻷﻋﺮاض
  
  (ﻻ(                             )ﻧﻌﻢ)هﻞ ﺗﺘﻌﺎﻃﻰ أي أدوﻳﺔ؟؟                                     
  
  __________ﻣﺎ ﻧﻮع اﻟﺪواء؟؟
  
  (ﻻ(                             )ﻧﻌﻢ)     ؟؟        21ﺣﻘﻦ ﻓﻴﺘﺎﻣﻴﻦ ب هﻞ ﺗﺘﻌﺎﻃﻰ ﺣﺒﻮب أو 
 ﻻ أن ﻋﻴﻨﺔ ﻣﻦ دﻣﻲ ﻟﻐﺮض اﻟﺒﺤﺚ اﻟﻌﻠﻤﻲ ﻋﻠﻰ إﻋﻄﺎءأواﻓﻖ ﻋﻠﻰ __________________ أدﻧﺎﻩأﻧﺎ اﻟﻤﻮﻗﻊ :ﻣﻮاﻓﻘﺔ  
 .ﺗﺴﺘﻌﻤﻞ ﻷي أﻏﺮاض أﺧﺮى
  
  ___________:اﻟﺘﻮﻗﻴﻊ
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Appendix B: Age, gender, general health status, and average serum vitamin B12 
results* of each participant.   
  
Sample 
number 
Age 
(year) 
Gender Mentionable 
diseases 
Have any of 
vitamin B12 
deficiency 
symptoms 
Taking 
vitamin B12 
supplements 
Average serum 
vitamin B12 
results* 
(pg/mL) 
1 25 M NO NO NO 233 
2 29 F NO NO NO 542 
3 23 M NO NO NO 234 
4 23 M NO NO NO 192 
5 
40 M 
Personal 
schizophrenia YES 
NO 
323 
6 42 M NO YES NO 187 
7 36 M NO NO NO 294 
8 35 M NO YES NO 313 
9 50 F NO YES NO 427 
10 50 F NO YES NO 714 
11 50 F NO YES NO 162 
12 42 F Arthritis YES NO 450 
13 40 M NO NO NO 310 
14 30 F NO YES NO 311 
15 45 M NO YES NO 267 
16 25 F NO YES NO 260 
17 26 F NO YES NO 361 
18 26 F NO YES NO 358 
19 22 F NO YES NO 270 
20 23 M NO NO NO 292 
21 28 F NO YES NO 495 
22 47 F H.pylori YES NO 316 
23 17 F NO YES NO 264 
24 53 M NO NO NO 359 
25 24 F NO YES NO 263 
26 22 F NO YES NO 215 
27 28 F NO YES NO 213 
28 23 F NO YES NO 364 
29 27 F NO YES NO 281 
 
* The average of the four results obtained after the analysis of each sample on; 
IMMULITE ®1000, TOSOH®, AxSYM system®, and ADVIA Centaur® System.  
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Appendix C: Serum vitamin B12 results (pg/mL) for 29 patients assayed by different 
machines. The highest and the lowest results for the same sample applied.    
Sample 
no. 
ADVIA ® TOSOH® IMMULITE 
®1000 
AxSYM® Highest-
lowest 
result* 
1 191** 221 266 253 75 
2 606*** 490 546 524 116 
3 300 196 213 226 104 
4 160 208 150 207 58 
5 363 244 352 332 119 
6 186 196 212 153 59 
7 312 254 295 314 58 
8 304 257 373 317 116 
9 356 426 507 419 151 
10 635 847 672 701 212 
11 144 173 150 168 29 
12 398 485 517 399 119 
13 340 237 345 319 108 
14 519 215 273 235 304 
15 225 206 397 240 191 
16 225 212 315 287 103 
17 370 254 439 379 185 
18 392 283 378 378 109 
19 252 236 323 269 87 
20 227 305 349 288 122 
21 515 415 533 515 118 
22 260 360 321 324 100 
23 241 232 268 316 75 
24 261 301 534 338 273 
25 381 302 192 175 189 
26 241 185 207 225 70 
27 141 212 269 228 128 
28 309 289 460 398 171 
29 249 252 335 286 86 
* The highest result – the lowest one for the same patient. 
** The blue color indicates the lowest result “for the same patient” between the four 
results.The red color indicates the highest result “for the same patient” between the four 
results. 
*** The average of (the highest result – the lowest) = 125 pg/mL. 
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  ﻓﻠﺴﻄﻴﻦ/ اﻟﻀﻔﺔ اﻟﻐﺮﺑﻴﺔ
  
  ﺳﻬﻴﺮ ﻓﺎﻳﺰ ﻣﺤﻤﻮد اﻟﺒﺮاﻏﻴﺜﻲ: إﻋﺪاد
   ﺧﺎﻟﺪ ﻳﻮﻧﺲ . د:ﻟﺪآﺘﻮرإﺷﺮاف ا
  
  اﻟﻤﻠﺨﺺ
  
 ﻳﻠﻌѧﺐ أدوارا رﺋﻴѧﺴﻴﺔ ﻓѧﻲ ﻋѧﺪة  ﻣѧﺴﺎرات ﺑﻴﻮآﻴﻤﻴﺎﺋﻴѧﺔ إذ أﺣﺪ أهﻢ اﻟﻌﻨﺎﺻﺮ ﻟﻠﺠѧﺴﻢ ،  21Bﻳﻌﺘﺒﺮ ﻓﻴﺘﺎﻣﻴﻦ 
ﺘﺎج ﻣﻮاد أﺧﺮى وﺳѧﻴﻄﺔ ﻣﻬﻤѧﺔ ﻓѧﻲ ﺗﻜѧﺮار اﻟﺤﻤѧﺾ اﻟﻨѧﻮوي وآѧﺬﻟﻚ ﺗﻠﻌѧﺐ هѧﺬﻩ اﻟﻤѧﻮاد دورا  إﻧ إﻟﻰﺗﻬﺪف 
 ﻳﻤﻜѧﻦ أن ﻳѧﺆدي إﻟѧﻰ ﻣﺠﻤﻮﻋѧﺔ واﺳѧﻌﺔ ﻣѧﻦ 21B ﻧﻘﺺ ﻓﻴﺘﺎﻣﻴﻦ إن. ﻣﻬﻤﺎ ﻟﻀﻤﺎن ﺻﺤﺔ اﻟﺠﻬﺎز اﻟﻌﺼﺒﻲ 
اﻻﺿﻄﺮاﺑﺎت اﻟﻌﺼﺒﻴﺔ واﻟﻨﻔﺴﻴﺔ و اﻟﺪﻣﻮﻳﺔ و اﻟﺘﻲ  ﻳﻤﻜﻦ ﺗﻔﺎدﻳﻬﺎ ﻋѧﻦ ﻃﺮﻳѧﻖ اﻟﺘѧﺸﺨﻴﺺ اﻟﻤﺒﻜѧﺮ واﻟﻌѧﻼج 
  .اﻟﻔﻮري
ﻬﺪف هﺬﻩ اﻟﺪراﺳﺔ إﻟﻰ ﻣﻘﺎرﻧﺔ ﻧﺘﺎﺋﺞ اﻟﺘﺤﻠﻴﻞ اﻵﻟﻲ ﻷرﺑﻌﺔ أﺟﻬѧﺰة ﻣѧﺴﺘﺨﺪﻣﺔ ﻋﻠѧﻰ ﻧﻄѧﺎق واﺳѧﻊ ﻟﻔﺤѧﺺ  ﺗ
®   ، mysxA®  اﻵﻻت اﻟﺘѧѧﻲ ﺗѧѧﻢ ﻣﻘﺎرﻧﺘﻬѧѧﺎ آﺎﻧѧѧﺖ ؛ إن. ﻓﻠѧѧﺴﻄﻴﻦ/  ﻓѧѧﻲ اﻟѧѧﻀﻔﺔ اﻟﻐﺮﺑﻴѧѧﺔ 21Bﻓﻴﺘѧѧﺎﻣﻴﻦ 
  .®HOSOT ، و 0002 ® etilummI  ، AIVDA
 ﻟﻜѧﻞ ﻋﻴﻨѧﺔ ﻣѧﺼﻞ ﻋﻠѧﻰ 21Bو ﻓﺤѧﺺ ﻓﻴﺘѧﺎﻣﻴﻦ  ﻣѧﺸﺎرآﺎ 03 ﻋﻴﻨﺎت ﻣﺼﻞ ﻣѧﻦ  أﺧﺪ ﺗﻢ ﻓﻲ هﺬﻩ اﻟﺪراﺳﺔ 
  .أرﺑﻌﺔ أﺟﻬﺰة ﺗﺤﻠﻴﻞ ﺁﻟﻲ ﻣﺨﺘﻠﻔﺔ ﻓﻲ ﺛﻼﺛﺔ ﻣﺨﺘﺒﺮات ﻣﺨﺘﻠﻔﺔ ﻓﻲ ﻣﺪﻳﻨﺔ رام اﷲ
 ارﺗﺒѧﺎط   وﺟﻮد ﻋﻼﻗﺔ إﻳﺠﺎﺑﻴﺔ هﺎﻣﺔ ﺑﻴﻦ اﻵﻻت ﻣѧﻊ درﺟѧﺎت “ ”rأﻇﻬﺮ ﺣﺴﺎب ﻣﻌﺎﻣﻞ اﻻرﺗﺒﺎط ﺑﻴﺮﺳﻮن 
ﺗﺮاوﺣѧﺖ  إذﺘﻠﻔﺔ و ﻣﺘﻔﺎوﺗﺔ أﻳﻀﺎ ،وآﺎﻧﺖ آﺬﻟﻚ ﻧﺘﻴﺠﺔ اﻟﻤﻴﻞ ﻣﺨ . 09.0  اﻟﻰ76.0 ﻣﺘﻔﺎوﺗﺔ، ﺗﺮاوﺣﺖ ﻣﻦ
 وهѧﻮ ﻣѧﺎ ﻳﻌﻜѧﺲ 6،431 ﻰ ﺣﺘѧ 2،23ﺎﻃﻊ ﻣﻊ اﻟﻤﺤﻮر اﻟﺼﺎدي ﻣﻦ آﻤﺎ ﺗﺮاوح اﻟﺘﻘ  . 18،0 اﻟﻰ 96،0ﻣﻦ 
  .اﻷﺟﻬﺰةوﺟﻮد ﺗﺤﻴﺰ ﺛﺎﺑﺖ وﻓﺮق واﺿﺢ ﺑﻴﻦ 
اﺗﻔѧﺎق " ﻢ ﻳѧﺴﺘﻮﻓﻲ ﺷѧﺮوط  اﻟﻤﻘﺎرﻧѧﺔ ، ﻓѧﺈن أﻳѧﺎ ﻣﻨﻬѧﺎ ﻟѧ اﻷﺟﻬѧﺰةﻋﻠѧﻰ اﻟѧﺮﻏﻢ ﻣѧﻦ وﺟѧﻮد ارﺗﺒѧﺎط آﺒﻴѧﺮ ﺑѧﻴﻦ 
 وأن 79.0اآﺒѧﺮ ﻣѧﻦ  “ ”rﻣﻌﺎﻣѧﻞ اﻻرﺗﺒѧﺎط ﺑﻴﺮﺳѧﻮن ﻳﻤﻜѧﻦ ﺗﻠﺨﻴѧﺼﻬﺎ ﺑѧﺄن ﺗﻜѧﻮن ﻧﺘﻴﺠѧﺔ  اﻟﺘѧﻲ "اﻷﺳѧﺎﻟﻴﺐ 
 ﻣﻦ  إن أي .1.1 و 09.0ﺗﻜﻮن ﻧﻘﻄﺔ اﻟﺘﻘﺎﻃﻊ ﻣﻊ اﻟﻤﺤﻮر اﻟﺼﺎدي ﻗﺮﻳﺒﺔ ﻟﻠﺼﻔﺮ وأن ﻳﻜﻮن اﻟﻤﻴﻞ ﻣﺎ ﺑﻴﻦ 
  .ﺔ اﻟﻨﺘﺎﺋﺞ ﺛﻠﺎﻤﻟﻤﻘﺎرﻧﺔ هﻲ ﻏﻴﺮ ﻣﺘ اﻬﺰةﺟاﻷ
 اﻟѧﺬي ﺗѧﻢ اﻟﺤѧﺼﻮل (VC) وﺟﻮد دﻗﺔ ﻓﻲ اﻟﺘﺤﻠﻴѧﻞ واﻟﺘѧﻲ ﻋﻜѧﺴﻬﺎ ﻣﻌﺎﻣѧﻞ اﻻﺧѧﺘﻼف أﻳﻀﺎأﻇﻬﺮت اﻟﻨﺘﺎﺋﺞ 
ﻟﻘﺪ ﺗﻢ اﻟﺤﺼﻮل ﻋﻠﻰ دﻗﺔ ﺟﻴﺪة ﻧﺴﺒﻴﺎ ﻣﻦ  .ﻋﻠﻴﻪ ﻣﻦ ﺗﻜﺮار اﻟﻌﻴﻨﺔ اﻟﻮاﺣﺪة ﻋﺸﺮ ﻣﺮات ﻋﻠﻰ اﻟﺠﻬﺎز اﻟﻮاﺣﺪ 
 .ةﺟﻬѧﺰ اﻷ ﺗﻤﺎﺷﺖ اﻟﺪﻗﺔ اﻟﺘﻲ ادﻋﺎهﺎ اﻟﻤﺼﻨﻊ ﻟﻜﻞ ﻣѧﻦ أﻧﻬﺎ اﻷرﺑﻌﺔ وﻳﻜﻤﻦ اﻋﺘﺒﺎرهﺎ ﻣﻘﺒﻮﻟﺔ ﺣﻴﺚ اﻷﺟﻬﺰة
ﻋﻠѧﻰ اﻷﺟﻬѧﺰة اﻷرﺑﻌѧﺔ   21Bﻟﻔﻴﺘѧﺎﻣﻴﻦ  002 Lm/gp ﻻ أن اﻟﻌﻴﻨﺔ اﻟﻮﺣﻴﺪة اﻟﺘﻲ أﻋﻄѧﺖ ﻧﺘѧﺎﺋﺞ اﻗѧﻞ ﻣѧﻦ إ
ﻓﻴﻤﺎ ﻋﺪا ذﻟﻚ آﺎن هﻨﺎك إﺧﻼف آﺒﻴﺮ ﺑﻴﻦ ﻧﺘﺎﺋﺞ اﻷﺟﻬﺰة اﻷرﺑﻌﺔ ﻟﻠﻌﻴﻨﺔ اﻟﻮاﺣѧﺪة  ﺣﻴѧﺚ , 11هﻲ ﻋﻴﻨﺔ رﻗﻢ 
  . ﺗﻀﺎﻋﻔﺖ ﺑﻌﺾ اﻟﻨﺘﺎﺋﺞ ﻋﻨﺪ ﻗﻴﺎﺳﻬﺎ ﻋﻠﻰ اﻷﺟﻬﺰة اﻟﻤﺨﺘﻠﻔﺔ
اﻷﺳѧﺎﻟﻴﺐ /  ﺑѧﻴﻦ ﻣﺨﺘﻠѧﻒ أﺟﻬѧﺰة ﺗﺤﻠﻴѧﻞ 21Bﻼﻓѧﺎت ﻓѧﻲ اﻟﻨﺘѧﺎﺋﺞ ﻣѧﺼﻞ ﻓﻴﺘѧﺎﻣﻴﻦ ﺗﺆآﺪ اﻟﺪراﺳѧﺔ وﺟѧﻮد اﺧﺘ 
  ﻓѧﻲ اﻟﺘѧﺸﺨﻴﺺ ﺑѧﻞ ﻩ ﻓѧﻲ اﻟﻤѧﺼﻞ ﻟﻮﺣѧﺪ 21B اﻟﺪراﺳﺔ ﺑﻌﺪم اﻻﻋﺘﻤѧﺎد ﻋﻠѧﻰ ﻗﻴѧﺎس ﻓﻴﺘѧﺎﻣﻴﻦ أوﺻﺖوﻋﻠﻴﻪ 
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 و ﻋﻠѧﻰ ﻓﻨﻴѧﻴﻦ اﻟﻤﺨﺘﺒѧﺮات  ﻠﻤѧﺮﻳﺾ  ﻟ أﻟѧﺴﺮﻳﺮي  اﻷﺧﺬ ﺑﻌﻴﻦ اﻻﻋﺘﺒѧﺎر اﻟﻔﺤѧﺺ ﻳﻨﺒﻐﻲ ﻋﻠﻰ اﻟﻄﺒﻴﺐ اﻟﻤﻌﺎﻟﺞ 
ﻓѧﻲ ( AMMﺑѧﺸﻜﻞ رﺋﻴѧﺴﻲ ) ﺗﺄآﻴﺪﻳѧﺔ ﻣﺜѧﻞ  ﻓﺤѧﺺ اﻟﻤﻨﺘﺠѧﺎت اﻷﻳѧﻀﻴﺔ أﺧѧﺮىرات  اﺧﺘﺒѧﺎﺑﺈدﺧѧﺎلاﻟﺒѧﺪء 
 ﻓﻲ اﻟﺪم هﻲ ﻓﻲ اﻟﻤﻨﻄﻘﺔ اﻟﺮﻣﺎدﻳﺔ اﻟﺘѧﻲ ﻻ ﺗﺆآѧﺪ 21B ﻋﻨﺪﻣﺎ ﺗﻜﻮن ﻧﺘﻴﺠﺔ ﻓﻴﺘﺎﻣﻴﻦ  ﺧﺎﺻﺔ ﻋﻤﻠﻬﻢ اﻟﺮوﺗﻴﻨﻲ 
 . ﺑﺸﻜﻞ ﻗﺎﻃﻊﻦاﻟﻔﻴﺘﺎﻣﻴأو ﺗﻨﻔﻲ وﺟﻮد ﻧﻘﺺ ﻓﻲ 
